id	sid	tid	token	lemma	pos
cord-257258-hu9oxea1	1	1	key	key	JJ
cord-257258-hu9oxea1	2	1	:	:	:
cord-257258-hu9oxea1	2	2	cord-257258-hu9oxea1	cord-257258-hu9oxea1	NNP
cord-257258-hu9oxea1	2	3	authors	author	NNS
cord-257258-hu9oxea1	2	4	:	:	:
cord-257258-hu9oxea1	2	5	Chabner	Chabner	NNP
cord-257258-hu9oxea1	2	6	,	,	,
cord-257258-hu9oxea1	2	7	Bruce	Bruce	NNP
cord-257258-hu9oxea1	2	8	A.	a.	NN
cord-257258-hu9oxea1	2	9	title	title	NN
cord-257258-hu9oxea1	2	10	:	:	:
cord-257258-hu9oxea1	2	11	Taking	take	VBG
cord-257258-hu9oxea1	2	12	the	the	DT
cord-257258-hu9oxea1	2	13	Longer	long	JJR
cord-257258-hu9oxea1	2	14	View	view	NN
cord-257258-hu9oxea1	2	15	of	of	IN
cord-257258-hu9oxea1	2	16	COVID‐19	COVID‐19	NNP
cord-257258-hu9oxea1	2	17	date	date	NN
cord-257258-hu9oxea1	2	18	:	:	:
cord-257258-hu9oxea1	2	19	2020	2020	CD
cord-257258-hu9oxea1	2	20	-	-	HYPH
cord-257258-hu9oxea1	2	21	04	04	CD
cord-257258-hu9oxea1	2	22	-	-	HYPH
cord-257258-hu9oxea1	2	23	27	27	CD
cord-257258-hu9oxea1	2	24	journal	journal	NN
cord-257258-hu9oxea1	2	25	:	:	:
cord-257258-hu9oxea1	3	1	Oncologist	oncologist	NN
cord-257258-hu9oxea1	3	2	DOI	doi	NN
cord-257258-hu9oxea1	3	3	:	:	:
cord-257258-hu9oxea1	4	1	10.1634	10.1634	CD
cord-257258-hu9oxea1	4	2	/	/	SYM
cord-257258-hu9oxea1	4	3	theoncologist.2020	theoncologist.2020	NN
cord-257258-hu9oxea1	4	4	-	-	HYPH
cord-257258-hu9oxea1	4	5	0313	0313	CD
cord-257258-hu9oxea1	4	6	sha	sha	NNP
cord-257258-hu9oxea1	4	7	:	:	:
cord-257258-hu9oxea1	5	1	9fb9d3ab604fb41ae5e3d83c1e5566d272a55acd	9fb9d3ab604fb41ae5e3d83c1e5566d272a55acd	LS
cord-257258-hu9oxea1	5	2	doc_id	doc_id	CD
cord-257258-hu9oxea1	5	3	:	:	:
cord-257258-hu9oxea1	6	1	257258	257258	CD
cord-257258-hu9oxea1	6	2	cord_uid	cord_uid	NNS
cord-257258-hu9oxea1	6	3	:	:	:
cord-257258-hu9oxea1	6	4	hu9oxea1	hu9oxea1	NNP
cord-257258-hu9oxea1	7	1	What	what	WP
cord-257258-hu9oxea1	7	2	are	be	VBP
cord-257258-hu9oxea1	7	3	the	the	DT
cord-257258-hu9oxea1	7	4	prospects	prospect	NNS
cord-257258-hu9oxea1	7	5	for	for	IN
cord-257258-hu9oxea1	7	6	dealing	deal	VBG
cord-257258-hu9oxea1	7	7	with	with	IN
cord-257258-hu9oxea1	7	8	COVID‐19	COVID‐19	NNP
cord-257258-hu9oxea1	7	9	more	more	RBR
cord-257258-hu9oxea1	7	10	effectively	effectively	RB
cord-257258-hu9oxea1	7	11	in	in	IN
cord-257258-hu9oxea1	7	12	the	the	DT
cord-257258-hu9oxea1	7	13	future	future	NN
cord-257258-hu9oxea1	7	14	?	?	.
cord-257258-hu9oxea1	8	1	This	this	DT
cord-257258-hu9oxea1	8	2	editorial	editorial	NN
cord-257258-hu9oxea1	8	3	addresses	address	VBZ
cord-257258-hu9oxea1	8	4	the	the	DT
cord-257258-hu9oxea1	8	5	question	question	NN
cord-257258-hu9oxea1	8	6	from	from	IN
cord-257258-hu9oxea1	8	7	the	the	DT
cord-257258-hu9oxea1	8	8	perspective	perspective	NN
cord-257258-hu9oxea1	8	9	of	of	IN
cord-257258-hu9oxea1	8	10	long‐term	long‐term	NNP
cord-257258-hu9oxea1	8	11	control	control	NN
cord-257258-hu9oxea1	8	12	of	of	IN
cord-257258-hu9oxea1	8	13	coronavirus	coronavirus	NN
cord-257258-hu9oxea1	8	14	infection	infection	NN
cord-257258-hu9oxea1	8	15	.	.	.
cord-257258-hu9oxea1	9	1	The	the	DT
cord-257258-hu9oxea1	9	2	U.S.	U.S.	NNP
cord-257258-hu9oxea1	9	3	health	health	NN
cord-257258-hu9oxea1	9	4	system	system	NN
cord-257258-hu9oxea1	9	5	and	and	CC
cord-257258-hu9oxea1	9	6	governmental	governmental	JJ
cord-257258-hu9oxea1	9	7	structures	structure	NNS
cord-257258-hu9oxea1	9	8	are	be	VBP
cord-257258-hu9oxea1	9	9	stressed	stress	VBN
cord-257258-hu9oxea1	9	10	to	to	IN
cord-257258-hu9oxea1	9	11	their	-PRON-	PRP$
cord-257258-hu9oxea1	9	12	limit	limit	NN
cord-257258-hu9oxea1	9	13	,	,	,
cord-257258-hu9oxea1	9	14	trying	try	VBG
cord-257258-hu9oxea1	9	15	to	to	TO
cord-257258-hu9oxea1	9	16	cope	cope	VB
cord-257258-hu9oxea1	9	17	with	with	IN
cord-257258-hu9oxea1	9	18	the	the	DT
cord-257258-hu9oxea1	9	19	devastating	devastating	JJ
cord-257258-hu9oxea1	9	20	effects	effect	NNS
cord-257258-hu9oxea1	9	21	of	of	IN
cord-257258-hu9oxea1	9	22	COVID-19	covid-19	NN
cord-257258-hu9oxea1	9	23	on	on	IN
cord-257258-hu9oxea1	9	24	patients	patient	NNS
cord-257258-hu9oxea1	9	25	,	,	,
cord-257258-hu9oxea1	9	26	on	on	IN
cord-257258-hu9oxea1	9	27	our	-PRON-	PRP$
cord-257258-hu9oxea1	9	28	community	community	NN
cord-257258-hu9oxea1	9	29	and	and	CC
cord-257258-hu9oxea1	9	30	family	family	NN
cord-257258-hu9oxea1	9	31	relationships	relationship	NNS
cord-257258-hu9oxea1	9	32	,	,	,
cord-257258-hu9oxea1	9	33	and	and	CC
cord-257258-hu9oxea1	9	34	on	on	IN
cord-257258-hu9oxea1	9	35	our	-PRON-	PRP$
cord-257258-hu9oxea1	9	36	national	national	JJ
cord-257258-hu9oxea1	9	37	economy	economy	NN
cord-257258-hu9oxea1	9	38	.	.	.
cord-257258-hu9oxea1	10	1	In	in	IN
cord-257258-hu9oxea1	10	2	the	the	DT
cord-257258-hu9oxea1	10	3	absence	absence	NN
cord-257258-hu9oxea1	10	4	of	of	IN
cord-257258-hu9oxea1	10	5	a	a	DT
cord-257258-hu9oxea1	10	6	vaccine	vaccine	NN
cord-257258-hu9oxea1	10	7	or	or	CC
cord-257258-hu9oxea1	10	8	effective	effective	JJ
cord-257258-hu9oxea1	10	9	antivirals	antiviral	NNS
cord-257258-hu9oxea1	10	10	,	,	,
cord-257258-hu9oxea1	10	11	social	social	JJ
cord-257258-hu9oxea1	10	12	distancing	distancing	NN
cord-257258-hu9oxea1	10	13	is	be	VBZ
cord-257258-hu9oxea1	10	14	currently	currently	RB
cord-257258-hu9oxea1	10	15	the	the	DT
cord-257258-hu9oxea1	10	16	primary	primary	JJ
cord-257258-hu9oxea1	10	17	public	public	JJ
cord-257258-hu9oxea1	10	18	health	health	NN
cord-257258-hu9oxea1	10	19	strategy	strategy	NN
cord-257258-hu9oxea1	10	20	for	for	IN
cord-257258-hu9oxea1	10	21	containing	contain	VBG
cord-257258-hu9oxea1	10	22	the	the	DT
cord-257258-hu9oxea1	10	23	epidemic	epidemic	NN
cord-257258-hu9oxea1	10	24	and	and	CC
cord-257258-hu9oxea1	10	25	has	have	VBZ
cord-257258-hu9oxea1	10	26	been	be	VBN
cord-257258-hu9oxea1	10	27	successful	successful	JJ
cord-257258-hu9oxea1	10	28	in	in	IN
cord-257258-hu9oxea1	10	29	South	South	NNP
cord-257258-hu9oxea1	10	30	Korea	Korea	NNP
cord-257258-hu9oxea1	10	31	and	and	CC
cord-257258-hu9oxea1	10	32	China	China	NNP
cord-257258-hu9oxea1	10	33	,	,	,
cord-257258-hu9oxea1	10	34	where	where	WRB
cord-257258-hu9oxea1	10	35	it	-PRON-	PRP
cord-257258-hu9oxea1	10	36	was	be	VBD
cord-257258-hu9oxea1	10	37	stringently	stringently	RB
cord-257258-hu9oxea1	10	38	employed	employ	VBN
cord-257258-hu9oxea1	10	39	.	.	.
cord-257258-hu9oxea1	11	1	In	in	IN
cord-257258-hu9oxea1	11	2	the	the	DT
cord-257258-hu9oxea1	11	3	U.S.	U.S.	NNP
cord-257258-hu9oxea1	11	4	,	,	,
cord-257258-hu9oxea1	11	5	it	-PRON-	PRP
cord-257258-hu9oxea1	11	6	has	have	VBZ
cord-257258-hu9oxea1	11	7	been	be	VBN
cord-257258-hu9oxea1	11	8	applied	apply	VBN
cord-257258-hu9oxea1	11	9	too	too	RB
cord-257258-hu9oxea1	11	10	late	late	RB
cord-257258-hu9oxea1	11	11	and	and	CC
cord-257258-hu9oxea1	11	12	in	in	IN
cord-257258-hu9oxea1	11	13	patchwork	patchwork	JJ
cord-257258-hu9oxea1	11	14	fashion	fashion	NN
cord-257258-hu9oxea1	11	15	on	on	IN
cord-257258-hu9oxea1	11	16	a	a	DT
cord-257258-hu9oxea1	11	17	national	national	JJ
cord-257258-hu9oxea1	11	18	level	level	NN
cord-257258-hu9oxea1	11	19	,	,	,
cord-257258-hu9oxea1	11	20	allowing	allow	VBG
cord-257258-hu9oxea1	11	21	the	the	DT
cord-257258-hu9oxea1	11	22	virus	virus	NN
cord-257258-hu9oxea1	11	23	to	to	TO
cord-257258-hu9oxea1	11	24	spread	spread	VB
cord-257258-hu9oxea1	11	25	broadly	broadly	RB
cord-257258-hu9oxea1	11	26	.	.	.
cord-257258-hu9oxea1	12	1	Home	home	NN
cord-257258-hu9oxea1	12	2	isolation	isolation	NN
cord-257258-hu9oxea1	12	3	and	and	CC
cord-257258-hu9oxea1	12	4	social	social	JJ
cord-257258-hu9oxea1	12	5	distancing	distancing	NN
cord-257258-hu9oxea1	12	6	measures	measure	NNS
cord-257258-hu9oxea1	12	7	inevitably	inevitably	RB
cord-257258-hu9oxea1	12	8	impede	impede	VBP
cord-257258-hu9oxea1	12	9	our	-PRON-	PRP$
cord-257258-hu9oxea1	12	10	ability	ability	NN
cord-257258-hu9oxea1	12	11	as	as	IN
cord-257258-hu9oxea1	12	12	physicians	physician	NNS
cord-257258-hu9oxea1	12	13	to	to	TO
cord-257258-hu9oxea1	12	14	care	care	VB
cord-257258-hu9oxea1	12	15	for	for	IN
cord-257258-hu9oxea1	12	16	patients	patient	NNS
cord-257258-hu9oxea1	12	17	with	with	IN
cord-257258-hu9oxea1	12	18	non	non	JJ
cord-257258-hu9oxea1	12	19	-	-	JJ
cord-257258-hu9oxea1	12	20	COVID-19	covid-19	JJ
cord-257258-hu9oxea1	12	21	illness	illness	NN
cord-257258-hu9oxea1	12	22	.	.	.
cord-257258-hu9oxea1	13	1	There	there	EX
cord-257258-hu9oxea1	13	2	is	be	VBZ
cord-257258-hu9oxea1	13	3	a	a	DT
cord-257258-hu9oxea1	13	4	very	very	RB
cord-257258-hu9oxea1	13	5	real	real	JJ
cord-257258-hu9oxea1	13	6	prospect	prospect	NN
cord-257258-hu9oxea1	13	7	of	of	IN
cord-257258-hu9oxea1	13	8	COVID-19	covid-19	JJ
cord-257258-hu9oxea1	13	9	recurring	recur	VBG
cord-257258-hu9oxea1	13	10	in	in	IN
cord-257258-hu9oxea1	13	11	epidemic	epidemic	NN
cord-257258-hu9oxea1	13	12	scale	scale	NN
cord-257258-hu9oxea1	13	13	among	among	IN
cord-257258-hu9oxea1	13	14	those	those	DT
cord-257258-hu9oxea1	13	15	not	not	RB
cord-257258-hu9oxea1	13	16	immune	immune	JJ
cord-257258-hu9oxea1	13	17	to	to	IN
cord-257258-hu9oxea1	13	18	the	the	DT
cord-257258-hu9oxea1	13	19	virus	virus	NN
cord-257258-hu9oxea1	13	20	.	.	.
cord-257258-hu9oxea1	14	1	What	what	WP
cord-257258-hu9oxea1	14	2	are	be	VBP
cord-257258-hu9oxea1	14	3	the	the	DT
cord-257258-hu9oxea1	14	4	prospects	prospect	NNS
cord-257258-hu9oxea1	14	5	for	for	IN
cord-257258-hu9oxea1	14	6	dealing	deal	VBG
cord-257258-hu9oxea1	14	7	with	with	IN
cord-257258-hu9oxea1	14	8	this	this	DT
cord-257258-hu9oxea1	14	9	virus	virus	NN
cord-257258-hu9oxea1	14	10	more	more	RBR
cord-257258-hu9oxea1	14	11	effectively	effectively	RB
cord-257258-hu9oxea1	14	12	in	in	IN
cord-257258-hu9oxea1	14	13	the	the	DT
cord-257258-hu9oxea1	14	14	future	future	NN
cord-257258-hu9oxea1	14	15	?	?	.
cord-257258-hu9oxea1	15	1	We	-PRON-	PRP
cord-257258-hu9oxea1	15	2	will	will	MD
cord-257258-hu9oxea1	15	3	need	need	VB
cord-257258-hu9oxea1	15	4	a	a	DT
cord-257258-hu9oxea1	15	5	more	more	RBR
cord-257258-hu9oxea1	15	6	timely	timely	JJ
cord-257258-hu9oxea1	15	7	and	and	CC
cord-257258-hu9oxea1	15	8	comprehensive	comprehensive	JJ
cord-257258-hu9oxea1	15	9	response	response	NN
cord-257258-hu9oxea1	15	10	by	by	IN
cord-257258-hu9oxea1	15	11	the	the	DT
cord-257258-hu9oxea1	15	12	federal	federal	JJ
cord-257258-hu9oxea1	15	13	government	government	NN
cord-257258-hu9oxea1	15	14	,	,	,
cord-257258-hu9oxea1	15	15	rather	rather	RB
cord-257258-hu9oxea1	15	16	than	than	IN
cord-257258-hu9oxea1	15	17	the	the	DT
cord-257258-hu9oxea1	15	18	weeks	week	NNS
cord-257258-hu9oxea1	15	19	of	of	IN
cord-257258-hu9oxea1	15	20	denial	denial	NN
cord-257258-hu9oxea1	15	21	,	,	,
cord-257258-hu9oxea1	15	22	delay	delay	NN
cord-257258-hu9oxea1	15	23	,	,	,
cord-257258-hu9oxea1	15	24	and	and	CC
cord-257258-hu9oxea1	15	25	incompetence	incompetence	NN
cord-257258-hu9oxea1	15	26	in	in	IN
cord-257258-hu9oxea1	15	27	developing	develop	VBG
cord-257258-hu9oxea1	15	28	tests	test	NNS
cord-257258-hu9oxea1	15	29	and	and	CC
cord-257258-hu9oxea1	15	30	enacting	enact	VBG
cord-257258-hu9oxea1	15	31	public	public	JJ
cord-257258-hu9oxea1	15	32	health	health	NN
cord-257258-hu9oxea1	15	33	measures	measure	NNS
cord-257258-hu9oxea1	15	34	.	.	.
cord-257258-hu9oxea1	16	1	We	-PRON-	PRP
cord-257258-hu9oxea1	16	2	will	will	MD
cord-257258-hu9oxea1	16	3	need	need	VB
cord-257258-hu9oxea1	16	4	international	international	JJ
cord-257258-hu9oxea1	16	5	cooperation	cooperation	NN
cord-257258-hu9oxea1	16	6	in	in	IN
cord-257258-hu9oxea1	16	7	sharing	share	VBG
cord-257258-hu9oxea1	16	8	information	information	NN
cord-257258-hu9oxea1	16	9	,	,	,
cord-257258-hu9oxea1	16	10	testing	testing	NN
cord-257258-hu9oxea1	16	11	and	and	CC
cord-257258-hu9oxea1	16	12	mitigation	mitigation	NN
cord-257258-hu9oxea1	16	13	strategies	strategy	NNS
cord-257258-hu9oxea1	16	14	,	,	,
cord-257258-hu9oxea1	16	15	and	and	CC
cord-257258-hu9oxea1	16	16	medical	medical	JJ
cord-257258-hu9oxea1	16	17	resources	resource	NNS
cord-257258-hu9oxea1	16	18	,	,	,
cord-257258-hu9oxea1	16	19	which	which	WDT
cord-257258-hu9oxea1	16	20	are	be	VBP
cord-257258-hu9oxea1	16	21	produced	produce	VBN
cord-257258-hu9oxea1	16	22	and	and	CC
cord-257258-hu9oxea1	16	23	sold	sell	VBN
cord-257258-hu9oxea1	16	24	on	on	IN
cord-257258-hu9oxea1	16	25	the	the	DT
cord-257258-hu9oxea1	16	26	international	international	JJ
cord-257258-hu9oxea1	16	27	market	market	NN
cord-257258-hu9oxea1	16	28	.	.	.
cord-257258-hu9oxea1	17	1	And	and	CC
cord-257258-hu9oxea1	17	2	we	-PRON-	PRP
cord-257258-hu9oxea1	17	3	will	will	MD
cord-257258-hu9oxea1	17	4	need	need	VB
cord-257258-hu9oxea1	17	5	drugs	drug	NNS
cord-257258-hu9oxea1	17	6	and	and	CC
cord-257258-hu9oxea1	17	7	vaccines	vaccine	NNS
cord-257258-hu9oxea1	17	8	.	.	.
cord-257258-hu9oxea1	18	1	The	the	DT
cord-257258-hu9oxea1	18	2	first	first	JJ
cord-257258-hu9oxea1	18	3	thought	thought	NN
cord-257258-hu9oxea1	18	4	in	in	IN
cord-257258-hu9oxea1	18	5	preventing	prevent	VBG
cord-257258-hu9oxea1	18	6	a	a	DT
cord-257258-hu9oxea1	18	7	recurrence	recurrence	NN
cord-257258-hu9oxea1	18	8	of	of	IN
cord-257258-hu9oxea1	18	9	COVID-19	covid-19	NN
cord-257258-hu9oxea1	18	10	is	be	VBZ
cord-257258-hu9oxea1	18	11	to	to	TO
cord-257258-hu9oxea1	18	12	develop	develop	VB
cord-257258-hu9oxea1	18	13	,	,	,
cord-257258-hu9oxea1	18	14	test	test	VB
cord-257258-hu9oxea1	18	15	,	,	,
cord-257258-hu9oxea1	18	16	and	and	CC
cord-257258-hu9oxea1	18	17	broadly	broadly	RB
cord-257258-hu9oxea1	18	18	administer	administer	VB
cord-257258-hu9oxea1	18	19	an	an	DT
cord-257258-hu9oxea1	18	20	effective	effective	JJ
cord-257258-hu9oxea1	18	21	vaccine	vaccine	NN
cord-257258-hu9oxea1	18	22	[	[	-LRB-
cord-257258-hu9oxea1	18	23	1	1	CD
cord-257258-hu9oxea1	18	24	]	]	-RRB-
cord-257258-hu9oxea1	18	25	.	.	.
cord-257258-hu9oxea1	19	1	The	the	DT
cord-257258-hu9oxea1	19	2	process	process	NN
cord-257258-hu9oxea1	19	3	of	of	IN
cord-257258-hu9oxea1	19	4	vaccine	vaccine	NN
cord-257258-hu9oxea1	19	5	development	development	NN
cord-257258-hu9oxea1	19	6	will	will	MD
cord-257258-hu9oxea1	19	7	require	require	VB
cord-257258-hu9oxea1	19	8	large	large	JJ
cord-257258-hu9oxea1	19	9	-	-	HYPH
cord-257258-hu9oxea1	19	10	scale	scale	NN
cord-257258-hu9oxea1	19	11	testing	testing	NN
cord-257258-hu9oxea1	19	12	in	in	IN
cord-257258-hu9oxea1	19	13	virus	virus	NN
cord-257258-hu9oxea1	19	14	-	-	HYPH
cord-257258-hu9oxea1	19	15	naïve	naïve	JJ
cord-257258-hu9oxea1	19	16	populations	population	NNS
cord-257258-hu9oxea1	19	17	,	,	,
cord-257258-hu9oxea1	19	18	will	will	MD
cord-257258-hu9oxea1	19	19	likely	likely	RB
cord-257258-hu9oxea1	19	20	take	take	VB
cord-257258-hu9oxea1	19	21	more	more	JJR
cord-257258-hu9oxea1	19	22	than	than	IN
cord-257258-hu9oxea1	19	23	one	one	CD
cord-257258-hu9oxea1	19	24	year	year	NN
cord-257258-hu9oxea1	19	25	,	,	,
cord-257258-hu9oxea1	19	26	and	and	CC
cord-257258-hu9oxea1	19	27	will	will	MD
cord-257258-hu9oxea1	19	28	require	require	VB
cord-257258-hu9oxea1	19	29	worldwide	worldwide	JJ
cord-257258-hu9oxea1	19	30	cooperation	cooperation	NN
cord-257258-hu9oxea1	19	31	[	[	-LRB-
cord-257258-hu9oxea1	19	32	2	2	CD
cord-257258-hu9oxea1	19	33	]	]	-RRB-
cord-257258-hu9oxea1	19	34	.	.	.
cord-257258-hu9oxea1	20	1	It	-PRON-	PRP
cord-257258-hu9oxea1	20	2	is	be	VBZ
cord-257258-hu9oxea1	20	3	not	not	RB
cord-257258-hu9oxea1	20	4	sufficient	sufficient	JJ
cord-257258-hu9oxea1	20	5	to	to	TO
cord-257258-hu9oxea1	20	6	stop	stop	VB
cord-257258-hu9oxea1	20	7	an	an	DT
cord-257258-hu9oxea1	20	8	epidemic	epidemic	NN
cord-257258-hu9oxea1	20	9	in	in	IN
cord-257258-hu9oxea1	20	10	one	one	CD
cord-257258-hu9oxea1	20	11	country	country	NN
cord-257258-hu9oxea1	20	12	,	,	,
cord-257258-hu9oxea1	20	13	given	give	VBN
cord-257258-hu9oxea1	20	14	the	the	DT
cord-257258-hu9oxea1	20	15	level	level	NN
cord-257258-hu9oxea1	20	16	of	of	IN
cord-257258-hu9oxea1	20	17	international	international	JJ
cord-257258-hu9oxea1	20	18	travel	travel	NN
cord-257258-hu9oxea1	20	19	and	and	CC
cord-257258-hu9oxea1	20	20	commerce	commerce	NN
cord-257258-hu9oxea1	20	21	.	.	.
cord-257258-hu9oxea1	21	1	That	that	DT
cord-257258-hu9oxea1	21	2	cooperation	cooperation	NN
cord-257258-hu9oxea1	21	3	must	must	MD
cord-257258-hu9oxea1	21	4	include	include	VB
cord-257258-hu9oxea1	21	5	China	China	NNP
cord-257258-hu9oxea1	21	6	,	,	,
cord-257258-hu9oxea1	21	7	which	which	WDT
cord-257258-hu9oxea1	21	8	has	have	VBZ
cord-257258-hu9oxea1	21	9	been	be	VBN
cord-257258-hu9oxea1	21	10	the	the	DT
cord-257258-hu9oxea1	21	11	source	source	NN
cord-257258-hu9oxea1	21	12	of	of	IN
cord-257258-hu9oxea1	21	13	several	several	JJ
cord-257258-hu9oxea1	21	14	coronavirus	coronavirus	NN
cord-257258-hu9oxea1	21	15	outbreaks	outbreak	NNS
cord-257258-hu9oxea1	21	16	and	and	CC
cord-257258-hu9oxea1	21	17	which	which	WDT
cord-257258-hu9oxea1	21	18	has	have	VBZ
cord-257258-hu9oxea1	21	19	the	the	DT
cord-257258-hu9oxea1	21	20	ability	ability	NN
cord-257258-hu9oxea1	21	21	to	to	TO
cord-257258-hu9oxea1	21	22	develop	develop	VB
cord-257258-hu9oxea1	21	23	and	and	CC
cord-257258-hu9oxea1	21	24	produce	produce	VB
cord-257258-hu9oxea1	21	25	vaccines	vaccine	NNS
cord-257258-hu9oxea1	21	26	on	on	IN
cord-257258-hu9oxea1	21	27	a	a	DT
cord-257258-hu9oxea1	21	28	massive	massive	JJ
cord-257258-hu9oxea1	21	29	scale	scale	NN
cord-257258-hu9oxea1	21	30	.	.	.
cord-257258-hu9oxea1	22	1	We	-PRON-	PRP
cord-257258-hu9oxea1	22	2	realized	realize	VBD
cord-257258-hu9oxea1	22	3	as	as	IN
cord-257258-hu9oxea1	22	4	a	a	DT
cord-257258-hu9oxea1	22	5	result	result	NN
cord-257258-hu9oxea1	22	6	of	of	IN
cord-257258-hu9oxea1	22	7	our	-PRON-	PRP$
cord-257258-hu9oxea1	22	8	current	current	JJ
cord-257258-hu9oxea1	22	9	experience	experience	NN
cord-257258-hu9oxea1	22	10	that	that	IN
cord-257258-hu9oxea1	22	11	China	China	NNP
cord-257258-hu9oxea1	22	12	is	be	VBZ
cord-257258-hu9oxea1	22	13	currently	currently	RB
cord-257258-hu9oxea1	22	14	the	the	DT
cord-257258-hu9oxea1	22	15	major	major	JJ
cord-257258-hu9oxea1	22	16	producer	producer	NN
cord-257258-hu9oxea1	22	17	of	of	IN
cord-257258-hu9oxea1	22	18	the	the	DT
cord-257258-hu9oxea1	22	19	world	world	NN
cord-257258-hu9oxea1	22	20	's	's	POS
cord-257258-hu9oxea1	22	21	medical	medical	JJ
cord-257258-hu9oxea1	22	22	equipment	equipment	NN
cord-257258-hu9oxea1	22	23	,	,	,
cord-257258-hu9oxea1	22	24	including	include	VBG
cord-257258-hu9oxea1	22	25	masks	mask	NNS
cord-257258-hu9oxea1	22	26	,	,	,
cord-257258-hu9oxea1	22	27	protective	protective	JJ
cord-257258-hu9oxea1	22	28	gowns	gown	NNS
cord-257258-hu9oxea1	22	29	,	,	,
cord-257258-hu9oxea1	22	30	and	and	CC
cord-257258-hu9oxea1	22	31	ventilators	ventilator	NNS
cord-257258-hu9oxea1	22	32	,	,	,
cord-257258-hu9oxea1	22	33	as	as	RB
cord-257258-hu9oxea1	22	34	well	well	RB
cord-257258-hu9oxea1	22	35	as	as	IN
cord-257258-hu9oxea1	22	36	the	the	DT
cord-257258-hu9oxea1	22	37	chemical	chemical	JJ
cord-257258-hu9oxea1	22	38	ingredients	ingredient	NNS
cord-257258-hu9oxea1	22	39	in	in	IN
cord-257258-hu9oxea1	22	40	most	most	JJS
cord-257258-hu9oxea1	22	41	of	of	IN
cord-257258-hu9oxea1	22	42	our	-PRON-	PRP$
cord-257258-hu9oxea1	22	43	medications	medication	NNS
cord-257258-hu9oxea1	22	44	.	.	.
cord-257258-hu9oxea1	23	1	A	a	DT
cord-257258-hu9oxea1	23	2	collaborative	collaborative	JJ
cord-257258-hu9oxea1	23	3	relationship	relationship	NN
cord-257258-hu9oxea1	23	4	with	with	IN
cord-257258-hu9oxea1	23	5	health	health	NN
cord-257258-hu9oxea1	23	6	authorities	authority	NNS
cord-257258-hu9oxea1	23	7	in	in	IN
cord-257258-hu9oxea1	23	8	China	China	NNP
cord-257258-hu9oxea1	23	9	will	will	MD
cord-257258-hu9oxea1	23	10	be	be	VB
cord-257258-hu9oxea1	23	11	crucial	crucial	JJ
cord-257258-hu9oxea1	23	12	to	to	IN
cord-257258-hu9oxea1	23	13	our	-PRON-	PRP$
cord-257258-hu9oxea1	23	14	ability	ability	NN
cord-257258-hu9oxea1	23	15	to	to	TO
cord-257258-hu9oxea1	23	16	cope	cope	VB
cord-257258-hu9oxea1	23	17	with	with	IN
cord-257258-hu9oxea1	23	18	future	future	JJ
cord-257258-hu9oxea1	23	19	epidemics	epidemic	NNS
cord-257258-hu9oxea1	23	20	.	.	.
cord-257258-hu9oxea1	24	1	Regarding	regard	VBG
cord-257258-hu9oxea1	24	2	the	the	DT
cord-257258-hu9oxea1	24	3	chances	chance	NNS
cord-257258-hu9oxea1	24	4	of	of	IN
cord-257258-hu9oxea1	24	5	creating	create	VBG
cord-257258-hu9oxea1	24	6	an	an	DT
cord-257258-hu9oxea1	24	7	effective	effective	JJ
cord-257258-hu9oxea1	24	8	vaccine	vaccine	NN
cord-257258-hu9oxea1	24	9	against	against	IN
cord-257258-hu9oxea1	24	10	SARS	SARS	NNP
cord-257258-hu9oxea1	24	11	-	-	HYPH
cord-257258-hu9oxea1	24	12	CoV-2	CoV-2	NNP
cord-257258-hu9oxea1	24	13	infection	infection	NN
cord-257258-hu9oxea1	24	14	,	,	,
cord-257258-hu9oxea1	24	15	in	in	IN
cord-257258-hu9oxea1	24	16	the	the	DT
cord-257258-hu9oxea1	24	17	U.S.	U.S.	NNP
cord-257258-hu9oxea1	24	18	the	the	DT
cord-257258-hu9oxea1	24	19	Biomedical	Biomedical	NNP
cord-257258-hu9oxea1	24	20	Advanced	Advanced	NNP
cord-257258-hu9oxea1	24	21	Research	Research	NNP
cord-257258-hu9oxea1	24	22	and	and	CC
cord-257258-hu9oxea1	24	23	Development	Development	NNP
cord-257258-hu9oxea1	24	24	Authority	Authority	NNP
cord-257258-hu9oxea1	24	25	(	(	-LRB-
cord-257258-hu9oxea1	24	26	BARDA	BARDA	NNP
cord-257258-hu9oxea1	24	27	)	)	-RRB-
cord-257258-hu9oxea1	24	28	of	of	IN
cord-257258-hu9oxea1	24	29	the	the	DT
cord-257258-hu9oxea1	24	30	Department	Department	NNP
cord-257258-hu9oxea1	24	31	of	of	IN
cord-257258-hu9oxea1	24	32	Health	Health	NNP
cord-257258-hu9oxea1	24	33	and	and	CC
cord-257258-hu9oxea1	24	34	Human	Human	NNP
cord-257258-hu9oxea1	24	35	Services	Services	NNPS
cord-257258-hu9oxea1	24	36	is	be	VBZ
cord-257258-hu9oxea1	24	37	devoting	devote	VBG
cord-257258-hu9oxea1	24	38	significant	significant	JJ
cord-257258-hu9oxea1	24	39	support	support	NN
cord-257258-hu9oxea1	24	40	for	for	IN
cord-257258-hu9oxea1	24	41	two	two	CD
cord-257258-hu9oxea1	24	42	currently	currently	RB
cord-257258-hu9oxea1	24	43	approved	approve	VBN
cord-257258-hu9oxea1	24	44	trials	trial	NNS
cord-257258-hu9oxea1	24	45	:	:	:
cord-257258-hu9oxea1	24	46	a	a	DT
cord-257258-hu9oxea1	24	47	lipid	lipid	NN
cord-257258-hu9oxea1	24	48	nanoparticle	nanoparticle	NN
cord-257258-hu9oxea1	24	49	vaccine	vaccine	NN
cord-257258-hu9oxea1	24	50	that	that	WDT
cord-257258-hu9oxea1	24	51	contains	contain	VBZ
cord-257258-hu9oxea1	24	52	mRNAs	mRNAs	NNPS
cord-257258-hu9oxea1	24	53	directing	direct	VBG
cord-257258-hu9oxea1	24	54	the	the	DT
cord-257258-hu9oxea1	24	55	synthesis	synthesis	NN
cord-257258-hu9oxea1	24	56	of	of	IN
cord-257258-hu9oxea1	24	57	the	the	DT
cord-257258-hu9oxea1	24	58	SARS	SARS	NNP
cord-257258-hu9oxea1	24	59	-	-	HYPH
cord-257258-hu9oxea1	24	60	CoV-2	CoV-2	NNP
cord-257258-hu9oxea1	24	61	spike	spike	NN
cord-257258-hu9oxea1	24	62	protein	protein	NN
cord-257258-hu9oxea1	24	63	(	(	-LRB-
cord-257258-hu9oxea1	24	64	Moderna	Moderna	NNP
cord-257258-hu9oxea1	24	65	)	)	-RRB-
cord-257258-hu9oxea1	24	66	and	and	CC
cord-257258-hu9oxea1	24	67	an	an	DT
cord-257258-hu9oxea1	24	68	adenovirus	adenovirus	NN
cord-257258-hu9oxea1	24	69	construct	construct	NN
cord-257258-hu9oxea1	24	70	of	of	IN
cord-257258-hu9oxea1	24	71	virus	virus	NN
cord-257258-hu9oxea1	24	72	material	material	NN
cord-257258-hu9oxea1	24	73	co	co	NN
cord-257258-hu9oxea1	24	74	-	-	VBN
cord-257258-hu9oxea1	24	75	supported	support	VBN
cord-257258-hu9oxea1	24	76	by	by	IN
cord-257258-hu9oxea1	24	77	Johnson	Johnson	NNP
cord-257258-hu9oxea1	24	78	&	&	CC
cord-257258-hu9oxea1	24	79	Johnson	Johnson	NNP
cord-257258-hu9oxea1	24	80	[	[	-LRB-
cord-257258-hu9oxea1	24	81	1	1	CD
cord-257258-hu9oxea1	24	82	]	]	-RRB-
cord-257258-hu9oxea1	24	83	.	.	.
cord-257258-hu9oxea1	25	1	The	the	DT
cord-257258-hu9oxea1	25	2	Wellcome	Wellcome	NNP
cord-257258-hu9oxea1	25	3	Trust	Trust	NNP
cord-257258-hu9oxea1	25	4	and	and	CC
cord-257258-hu9oxea1	25	5	Gates	Gates	NNP
cord-257258-hu9oxea1	25	6	Foundation	Foundation	NNP
cord-257258-hu9oxea1	25	7	have	have	VBP
cord-257258-hu9oxea1	25	8	implemented	implement	VBN
cord-257258-hu9oxea1	25	9	an	an	DT
cord-257258-hu9oxea1	25	10	international	international	JJ
cord-257258-hu9oxea1	25	11	effort	effort	NN
cord-257258-hu9oxea1	25	12	,	,	,
cord-257258-hu9oxea1	25	13	the	the	DT
cord-257258-hu9oxea1	25	14	Coalition	Coalition	NNP
cord-257258-hu9oxea1	25	15	for	for	IN
cord-257258-hu9oxea1	25	16	Epidemic	Epidemic	NNP
cord-257258-hu9oxea1	25	17	Preparedness	Preparedness	NNP
cord-257258-hu9oxea1	25	18	Innovation	Innovation	NNP
cord-257258-hu9oxea1	25	19	(	(	-LRB-
cord-257258-hu9oxea1	25	20	CEPI	CEPI	NNP
cord-257258-hu9oxea1	25	21	)	)	-RRB-
cord-257258-hu9oxea1	25	22	,	,	,
cord-257258-hu9oxea1	25	23	to	to	TO
cord-257258-hu9oxea1	25	24	select	select	VB
cord-257258-hu9oxea1	25	25	and	and	CC
cord-257258-hu9oxea1	25	26	promote	promote	VB
cord-257258-hu9oxea1	25	27	the	the	DT
cord-257258-hu9oxea1	25	28	development	development	NN
cord-257258-hu9oxea1	25	29	of	of	IN
cord-257258-hu9oxea1	25	30	three	three	CD
cord-257258-hu9oxea1	25	31	promising	promising	JJ
cord-257258-hu9oxea1	25	32	vaccines	vaccine	NNS
cord-257258-hu9oxea1	25	33	,	,	,
cord-257258-hu9oxea1	25	34	with	with	IN
cord-257258-hu9oxea1	25	35	the	the	DT
cord-257258-hu9oxea1	25	36	intent	intent	NN
cord-257258-hu9oxea1	25	37	to	to	TO
cord-257258-hu9oxea1	25	38	achieve	achieve	VB
cord-257258-hu9oxea1	25	39	worldwide	worldwide	JJ
cord-257258-hu9oxea1	25	40	distribution	distribution	NN
cord-257258-hu9oxea1	25	41	of	of	IN
cord-257258-hu9oxea1	25	42	an	an	DT
cord-257258-hu9oxea1	25	43	effective	effective	JJ
cord-257258-hu9oxea1	25	44	agent	agent	NN
cord-257258-hu9oxea1	25	45	in	in	IN
cord-257258-hu9oxea1	25	46	the	the	DT
cord-257258-hu9oxea1	25	47	next	next	JJ
cord-257258-hu9oxea1	25	48	year	year	NN
cord-257258-hu9oxea1	25	49	[	[	-LRB-
cord-257258-hu9oxea1	25	50	3	3	CD
cord-257258-hu9oxea1	25	51	]	]	-RRB-
cord-257258-hu9oxea1	25	52	.	.	.
cord-257258-hu9oxea1	26	1	Multiple	multiple	JJ
cord-257258-hu9oxea1	26	2	other	other	JJ
cord-257258-hu9oxea1	26	3	approaches	approach	NNS
cord-257258-hu9oxea1	26	4	to	to	IN
cord-257258-hu9oxea1	26	5	vaccine	vaccine	NN
cord-257258-hu9oxea1	26	6	development	development	NN
cord-257258-hu9oxea1	26	7	are	be	VBP
cord-257258-hu9oxea1	26	8	in	in	IN
cord-257258-hu9oxea1	26	9	play	play	NN
cord-257258-hu9oxea1	26	10	,	,	,
cord-257258-hu9oxea1	26	11	including	include	VBG
cord-257258-hu9oxea1	26	12	the	the	DT
cord-257258-hu9oxea1	26	13	use	use	NN
cord-257258-hu9oxea1	26	14	of	of	IN
cord-257258-hu9oxea1	26	15	DNA	DNA	NNP
cord-257258-hu9oxea1	26	16	and	and	CC
cord-257258-hu9oxea1	26	17	mRNA	mrna	NN
cord-257258-hu9oxea1	26	18	vectors	vector	NNS
cord-257258-hu9oxea1	26	19	,	,	,
cord-257258-hu9oxea1	26	20	as	as	RB
cord-257258-hu9oxea1	26	21	well	well	RB
cord-257258-hu9oxea1	26	22	as	as	IN
cord-257258-hu9oxea1	26	23	viral	viral	JJ
cord-257258-hu9oxea1	26	24	proteins	protein	NNS
cord-257258-hu9oxea1	26	25	and	and	CC
cord-257258-hu9oxea1	26	26	peptide	peptide	NN
cord-257258-hu9oxea1	26	27	epitopes	epitope	NNS
cord-257258-hu9oxea1	26	28	,	,	,
cord-257258-hu9oxea1	26	29	delivered	deliver	VBN
cord-257258-hu9oxea1	26	30	in	in	IN
cord-257258-hu9oxea1	26	31	different	different	JJ
cord-257258-hu9oxea1	26	32	formulations	formulation	NNS
cord-257258-hu9oxea1	26	33	and	and	CC
cord-257258-hu9oxea1	26	34	with	with	IN
cord-257258-hu9oxea1	26	35	different	different	JJ
cord-257258-hu9oxea1	26	36	adjuvants	adjuvant	NNS
cord-257258-hu9oxea1	26	37	.	.	.
cord-257258-hu9oxea1	27	1	Proving	prove	VBG
cord-257258-hu9oxea1	27	2	efficacy	efficacy	NN
cord-257258-hu9oxea1	27	3	and	and	CC
cord-257258-hu9oxea1	27	4	safety	safety	NN
cord-257258-hu9oxea1	27	5	in	in	IN
cord-257258-hu9oxea1	27	6	large	large	JJ
cord-257258-hu9oxea1	27	7	-	-	HYPH
cord-257258-hu9oxea1	27	8	scale	scale	NN
cord-257258-hu9oxea1	27	9	randomized	randomized	JJ
cord-257258-hu9oxea1	27	10	trials	trial	NNS
cord-257258-hu9oxea1	27	11	is	be	VBZ
cord-257258-hu9oxea1	27	12	the	the	DT
cord-257258-hu9oxea1	27	13	critical	critical	JJ
cord-257258-hu9oxea1	27	14	step	step	NN
cord-257258-hu9oxea1	27	15	that	that	WDT
cord-257258-hu9oxea1	27	16	determines	determine	VBZ
cord-257258-hu9oxea1	27	17	failure	failure	NN
cord-257258-hu9oxea1	27	18	or	or	CC
cord-257258-hu9oxea1	27	19	success	success	NN
cord-257258-hu9oxea1	27	20	,	,	,
cord-257258-hu9oxea1	27	21	and	and	CC
cord-257258-hu9oxea1	27	22	all	all	DT
cord-257258-hu9oxea1	27	23	of	of	IN
cord-257258-hu9oxea1	27	24	this	this	DT
cord-257258-hu9oxea1	27	25	will	will	MD
cord-257258-hu9oxea1	27	26	take	take	VB
cord-257258-hu9oxea1	27	27	many	many	JJ
cord-257258-hu9oxea1	27	28	months	month	NNS
cord-257258-hu9oxea1	27	29	,	,	,
cord-257258-hu9oxea1	27	30	if	if	IN
cord-257258-hu9oxea1	27	31	not	not	RB
cord-257258-hu9oxea1	27	32	1	1	CD
cord-257258-hu9oxea1	27	33	-	-	SYM
cord-257258-hu9oxea1	27	34	2	2	CD
cord-257258-hu9oxea1	27	35	years	year	NNS
cord-257258-hu9oxea1	27	36	.	.	.
cord-257258-hu9oxea1	28	1	While	while	IN
cord-257258-hu9oxea1	28	2	vaccine	vaccine	NN
cord-257258-hu9oxea1	28	3	development	development	NN
cord-257258-hu9oxea1	28	4	has	have	VBZ
cord-257258-hu9oxea1	28	5	an	an	DT
cord-257258-hu9oxea1	28	6	obvious	obvious	JJ
cord-257258-hu9oxea1	28	7	high	high	JJ
cord-257258-hu9oxea1	28	8	priority	priority	NN
cord-257258-hu9oxea1	28	9	,	,	,
cord-257258-hu9oxea1	28	10	much	much	JJ
cord-257258-hu9oxea1	28	11	attention	attention	NN
cord-257258-hu9oxea1	28	12	has	have	VBZ
cord-257258-hu9oxea1	28	13	also	also	RB
cord-257258-hu9oxea1	28	14	been	be	VBN
cord-257258-hu9oxea1	28	15	given	give	VBN
cord-257258-hu9oxea1	28	16	in	in	IN
cord-257258-hu9oxea1	28	17	the	the	DT
cord-257258-hu9oxea1	28	18	press	press	NN
cord-257258-hu9oxea1	28	19	and	and	CC
cord-257258-hu9oxea1	28	20	in	in	IN
cord-257258-hu9oxea1	28	21	discussions	discussion	NNS
cord-257258-hu9oxea1	28	22	of	of	IN
cord-257258-hu9oxea1	28	23	the	the	DT
cord-257258-hu9oxea1	28	24	White	White	NNP
cord-257258-hu9oxea1	28	25	House	House	NNP
cord-257258-hu9oxea1	28	26	Task	Task	NNP
cord-257258-hu9oxea1	28	27	Force	Force	NNP
cord-257258-hu9oxea1	28	28	to	to	IN
cord-257258-hu9oxea1	28	29	the	the	DT
cord-257258-hu9oxea1	28	30	development	development	NN
cord-257258-hu9oxea1	28	31	of	of	IN
cord-257258-hu9oxea1	28	32	effective	effective	JJ
cord-257258-hu9oxea1	28	33	antiviral	antiviral	JJ
cord-257258-hu9oxea1	28	34	drugs	drug	NNS
cord-257258-hu9oxea1	28	35	.	.	.
cord-257258-hu9oxea1	29	1	Drugs	drug	NNS
cord-257258-hu9oxea1	29	2	may	may	MD
cord-257258-hu9oxea1	29	3	have	have	VB
cord-257258-hu9oxea1	29	4	a	a	DT
cord-257258-hu9oxea1	29	5	greater	great	JJR
cord-257258-hu9oxea1	29	6	chance	chance	NN
cord-257258-hu9oxea1	29	7	of	of	IN
cord-257258-hu9oxea1	29	8	early	early	JJ
cord-257258-hu9oxea1	29	9	success	success	NN
cord-257258-hu9oxea1	29	10	.	.	.
cord-257258-hu9oxea1	30	1	Thus	thus	RB
cord-257258-hu9oxea1	30	2	far	far	RB
cord-257258-hu9oxea1	30	3	,	,	,
cord-257258-hu9oxea1	30	4	the	the	DT
cord-257258-hu9oxea1	30	5	public	public	JJ
cord-257258-hu9oxea1	30	6	discourse	discourse	NN
cord-257258-hu9oxea1	30	7	has	have	VBZ
cord-257258-hu9oxea1	30	8	generated	generate	VBN
cord-257258-hu9oxea1	30	9	significant	significant	JJ
cord-257258-hu9oxea1	30	10	confusion	confusion	NN
cord-257258-hu9oxea1	30	11	and	and	CC
cord-257258-hu9oxea1	30	12	misconception	misconception	NN
cord-257258-hu9oxea1	30	13	.	.	.
cord-257258-hu9oxea1	31	1	The	the	DT
cord-257258-hu9oxea1	31	2	President	President	NNP
cord-257258-hu9oxea1	31	3	has	have	VBZ
cord-257258-hu9oxea1	31	4	touted	tout	VBN
cord-257258-hu9oxea1	31	5	the	the	DT
cord-257258-hu9oxea1	31	6	benefits	benefit	NNS
cord-257258-hu9oxea1	31	7	of	of	IN
cord-257258-hu9oxea1	31	8	hydroxychloroquine	hydroxychloroquine	NN
cord-257258-hu9oxea1	31	9	(	(	-LRB-
cord-257258-hu9oxea1	31	10	HQ	HQ	NNP
cord-257258-hu9oxea1	31	11	)	)	-RRB-
cord-257258-hu9oxea1	31	12	and	and	CC
cord-257258-hu9oxea1	31	13	advocated	advocate	VBD
cord-257258-hu9oxea1	31	14	its	-PRON-	PRP$
cord-257258-hu9oxea1	31	15	off	off	JJ
cord-257258-hu9oxea1	31	16	-	-	HYPH
cord-257258-hu9oxea1	31	17	label	label	NN
cord-257258-hu9oxea1	31	18	use	use	NN
cord-257258-hu9oxea1	31	19	,	,	,
cord-257258-hu9oxea1	31	20	and	and	CC
cord-257258-hu9oxea1	31	21	the	the	DT
cord-257258-hu9oxea1	31	22	FDA	FDA	NNP
cord-257258-hu9oxea1	31	23	has	have	VBZ
cord-257258-hu9oxea1	31	24	surprisingly	surprisingly	RB
cord-257258-hu9oxea1	31	25	endorsed	endorse	VBN
cord-257258-hu9oxea1	31	26	his	-PRON-	PRP$
cord-257258-hu9oxea1	31	27	position	position	NN
cord-257258-hu9oxea1	31	28	by	by	IN
cord-257258-hu9oxea1	31	29	granting	grant	VBG
cord-257258-hu9oxea1	31	30	an	an	DT
cord-257258-hu9oxea1	31	31	emergency	emergency	NN
cord-257258-hu9oxea1	31	32	approval	approval	NN
cord-257258-hu9oxea1	31	33	for	for	IN
cord-257258-hu9oxea1	31	34	COVID-19	covid-19	JJ
cord-257258-hu9oxea1	31	35	patients	patient	NNS
cord-257258-hu9oxea1	31	36	.	.	.
cord-257258-hu9oxea1	32	1	The	the	DT
cord-257258-hu9oxea1	32	2	laboratory	laboratory	NN
cord-257258-hu9oxea1	32	3	evidence	evidence	NN
cord-257258-hu9oxea1	32	4	that	that	IN
cord-257258-hu9oxea1	32	5	HQ	HQ	NNP
cord-257258-hu9oxea1	32	6	has	have	VBZ
cord-257258-hu9oxea1	32	7	antiviral	antiviral	JJ
cord-257258-hu9oxea1	32	8	effects	effect	NNS
cord-257258-hu9oxea1	32	9	is	be	VBZ
cord-257258-hu9oxea1	32	10	minimal	minimal	JJ
cord-257258-hu9oxea1	32	11	.	.	.
cord-257258-hu9oxea1	33	1	It	-PRON-	PRP
cord-257258-hu9oxea1	33	2	suppresses	suppress	VBZ
cord-257258-hu9oxea1	33	3	viral	viral	JJ
cord-257258-hu9oxea1	33	4	replication	replication	NN
cord-257258-hu9oxea1	33	5	only	only	RB
cord-257258-hu9oxea1	33	6	at	at	IN
cord-257258-hu9oxea1	33	7	very	very	RB
cord-257258-hu9oxea1	33	8	high	high	JJ
cord-257258-hu9oxea1	33	9	,	,	,
cord-257258-hu9oxea1	33	10	nonpharmacological	nonpharmacological	JJ
cord-257258-hu9oxea1	33	11	drug	drug	NN
cord-257258-hu9oxea1	33	12	concentrations	concentration	NNS
cord-257258-hu9oxea1	33	13	[	[	-LRB-
cord-257258-hu9oxea1	33	14	4	4	CD
cord-257258-hu9oxea1	33	15	]	]	-RRB-
cord-257258-hu9oxea1	33	16	.	.	.
cord-257258-hu9oxea1	34	1	The	the	DT
cord-257258-hu9oxea1	34	2	clinical	clinical	JJ
cord-257258-hu9oxea1	34	3	evidence	evidence	NN
cord-257258-hu9oxea1	34	4	for	for	IN
cord-257258-hu9oxea1	34	5	HQ	HQ	NNP
cord-257258-hu9oxea1	34	6	efficacy	efficacy	NN
cord-257258-hu9oxea1	34	7	comes	come	VBZ
cord-257258-hu9oxea1	34	8	from	from	IN
cord-257258-hu9oxea1	34	9	several	several	JJ
cord-257258-hu9oxea1	34	10	conflicting	conflict	VBG
cord-257258-hu9oxea1	34	11	reports	report	NNS
cord-257258-hu9oxea1	34	12	from	from	IN
cord-257258-hu9oxea1	34	13	China	China	NNP
cord-257258-hu9oxea1	34	14	and	and	CC
cord-257258-hu9oxea1	34	15	an	an	DT
cord-257258-hu9oxea1	34	16	article	article	NN
cord-257258-hu9oxea1	34	17	in	in	IN
cord-257258-hu9oxea1	34	18	the	the	DT
cord-257258-hu9oxea1	34	19	International	International	NNP
cord-257258-hu9oxea1	34	20	Journal	Journal	NNP
cord-257258-hu9oxea1	34	21	of	of	IN
cord-257258-hu9oxea1	34	22	Antimicrobial	Antimicrobial	NNP
cord-257258-hu9oxea1	34	23	Agents	Agents	NNPS
cord-257258-hu9oxea1	34	24	[	[	-LRB-
cord-257258-hu9oxea1	34	25	5	5	CD
cord-257258-hu9oxea1	34	26	]	]	-RRB-
cord-257258-hu9oxea1	34	27	,	,	,
cord-257258-hu9oxea1	34	28	describing	describe	VBG
cord-257258-hu9oxea1	34	29	a	a	DT
cord-257258-hu9oxea1	34	30	poorly	poorly	RB
cord-257258-hu9oxea1	34	31	performed	perform	VBN
cord-257258-hu9oxea1	34	32	,	,	,
cord-257258-hu9oxea1	34	33	uncontrolled	uncontrolled	JJ
cord-257258-hu9oxea1	34	34	French	french	JJ
cord-257258-hu9oxea1	34	35	study	study	NN
cord-257258-hu9oxea1	34	36	,	,	,
cord-257258-hu9oxea1	34	37	which	which	WDT
cord-257258-hu9oxea1	34	38	has	have	VBZ
cord-257258-hu9oxea1	34	39	been	be	VBN
cord-257258-hu9oxea1	34	40	sharply	sharply	RB
cord-257258-hu9oxea1	34	41	criticized	criticize	VBN
cord-257258-hu9oxea1	34	42	by	by	IN
cord-257258-hu9oxea1	34	43	the	the	DT
cord-257258-hu9oxea1	34	44	journal	journal	NN
cord-257258-hu9oxea1	34	45	sponsor	sponsor	NN
cord-257258-hu9oxea1	34	46	,	,	,
cord-257258-hu9oxea1	34	47	the	the	DT
cord-257258-hu9oxea1	34	48	International	International	NNP
cord-257258-hu9oxea1	34	49	Society	Society	NNP
cord-257258-hu9oxea1	34	50	of	of	IN
cord-257258-hu9oxea1	34	51	Antimicrobial	Antimicrobial	NNP
cord-257258-hu9oxea1	34	52	Chemotherapy	Chemotherapy	NNP
cord-257258-hu9oxea1	34	53	[	[	-LRB-
cord-257258-hu9oxea1	34	54	5	5	CD
cord-257258-hu9oxea1	34	55	]	]	-RRB-
cord-257258-hu9oxea1	34	56	.	.	.
cord-257258-hu9oxea1	35	1	The	the	DT
cord-257258-hu9oxea1	35	2	President	President	NNP
cord-257258-hu9oxea1	35	3	's	's	POS
cord-257258-hu9oxea1	35	4	endorsement	endorsement	NN
cord-257258-hu9oxea1	35	5	of	of	IN
cord-257258-hu9oxea1	35	6	hydroxychloroquine	hydroxychloroquine	NNP
cord-257258-hu9oxea1	35	7	has	have	VBZ
cord-257258-hu9oxea1	35	8	raised	raise	VBN
cord-257258-hu9oxea1	35	9	concern	concern	NN
cord-257258-hu9oxea1	35	10	among	among	IN
cord-257258-hu9oxea1	35	11	scientists	scientist	NNS
cord-257258-hu9oxea1	35	12	and	and	CC
cord-257258-hu9oxea1	35	13	clinicians	clinician	NNS
cord-257258-hu9oxea1	35	14	at	at	IN
cord-257258-hu9oxea1	35	15	many	many	JJ
cord-257258-hu9oxea1	35	16	levels	level	NNS
cord-257258-hu9oxea1	35	17	,	,	,
cord-257258-hu9oxea1	35	18	not	not	RB
cord-257258-hu9oxea1	35	19	simply	simply	RB
cord-257258-hu9oxea1	35	20	because	because	IN
cord-257258-hu9oxea1	35	21	of	of	IN
cord-257258-hu9oxea1	35	22	the	the	DT
cord-257258-hu9oxea1	35	23	lack	lack	NN
cord-257258-hu9oxea1	35	24	of	of	IN
cord-257258-hu9oxea1	35	25	convincing	convincing	JJ
cord-257258-hu9oxea1	35	26	data	datum	NNS
cord-257258-hu9oxea1	35	27	to	to	TO
cord-257258-hu9oxea1	35	28	support	support	VB
cord-257258-hu9oxea1	35	29	its	-PRON-	PRP$
cord-257258-hu9oxea1	35	30	general	general	JJ
cord-257258-hu9oxea1	35	31	use	use	NN
cord-257258-hu9oxea1	35	32	against	against	IN
cord-257258-hu9oxea1	35	33	COVID-19	COVID-19	NNP
cord-257258-hu9oxea1	35	34	.	.	.
cord-257258-hu9oxea1	36	1	The	the	DT
cord-257258-hu9oxea1	36	2	wide	wide	RB
cord-257258-hu9oxea1	36	3	-	-	HYPH
cord-257258-hu9oxea1	36	4	ranging	range	VBG
cord-257258-hu9oxea1	36	5	and	and	CC
cord-257258-hu9oxea1	36	6	unsupervised	unsupervised	JJ
cord-257258-hu9oxea1	36	7	deployment	deployment	NN
cord-257258-hu9oxea1	36	8	of	of	IN
cord-257258-hu9oxea1	36	9	this	this	DT
cord-257258-hu9oxea1	36	10	medication	medication	NN
cord-257258-hu9oxea1	36	11	will	will	MD
cord-257258-hu9oxea1	36	12	undoubtedly	undoubtedly	RB
cord-257258-hu9oxea1	36	13	affect	affect	VB
cord-257258-hu9oxea1	36	14	the	the	DT
cord-257258-hu9oxea1	36	15	ability	ability	NN
cord-257258-hu9oxea1	36	16	of	of	IN
cord-257258-hu9oxea1	36	17	serious	serious	JJ
cord-257258-hu9oxea1	36	18	researchers	researcher	NNS
cord-257258-hu9oxea1	36	19	to	to	TO
cord-257258-hu9oxea1	36	20	recruit	recruit	VB
cord-257258-hu9oxea1	36	21	patients	patient	NNS
cord-257258-hu9oxea1	36	22	to	to	IN
cord-257258-hu9oxea1	36	23	randomized	randomized	JJ
cord-257258-hu9oxea1	36	24	trials	trial	NNS
cord-257258-hu9oxea1	36	25	of	of	IN
cord-257258-hu9oxea1	36	26	this	this	DT
cord-257258-hu9oxea1	36	27	drug	drug	NN
cord-257258-hu9oxea1	36	28	and	and	CC
cord-257258-hu9oxea1	36	29	to	to	IN
cord-257258-hu9oxea1	36	30	trials	trial	NNS
cord-257258-hu9oxea1	36	31	of	of	IN
cord-257258-hu9oxea1	36	32	other	other	JJ
cord-257258-hu9oxea1	36	33	more	more	RBR
cord-257258-hu9oxea1	36	34	promising	promising	JJ
cord-257258-hu9oxea1	36	35	agents	agent	NNS
cord-257258-hu9oxea1	36	36	.	.	.
cord-257258-hu9oxea1	37	1	Despite	despite	IN
cord-257258-hu9oxea1	37	2	the	the	DT
cord-257258-hu9oxea1	37	3	assertion	assertion	NN
cord-257258-hu9oxea1	37	4	,	,	,
cord-257258-hu9oxea1	37	5	"	"	``
cord-257258-hu9oxea1	37	6	What	what	WP
cord-257258-hu9oxea1	37	7	have	have	VBP
cord-257258-hu9oxea1	37	8	you	-PRON-	PRP
cord-257258-hu9oxea1	37	9	got	get	VBN
cord-257258-hu9oxea1	37	10	to	to	TO
cord-257258-hu9oxea1	37	11	lose	lose	VB
cord-257258-hu9oxea1	37	12	!	!	.
cord-257258-hu9oxea1	37	13	"	"	''
cord-257258-hu9oxea1	37	14	,	,	,
cord-257258-hu9oxea1	37	15	there	there	EX
cord-257258-hu9oxea1	37	16	are	be	VBP
cord-257258-hu9oxea1	37	17	serious	serious	JJ
cord-257258-hu9oxea1	37	18	risks	risk	NNS
cord-257258-hu9oxea1	37	19	with	with	IN
cord-257258-hu9oxea1	37	20	introducing	introduce	VBG
cord-257258-hu9oxea1	37	21	any	any	DT
cord-257258-hu9oxea1	37	22	new	new	JJ
cord-257258-hu9oxea1	37	23	medication	medication	NN
cord-257258-hu9oxea1	37	24	,	,	,
cord-257258-hu9oxea1	37	25	particularly	particularly	RB
cord-257258-hu9oxea1	37	26	in	in	IN
cord-257258-hu9oxea1	37	27	severely	severely	RB
cord-257258-hu9oxea1	37	28	ill	ill	JJ
cord-257258-hu9oxea1	37	29	people	people	NNS
cord-257258-hu9oxea1	37	30	.	.	.
cord-257258-hu9oxea1	38	1	Hydroxychloroquine	Hydroxychloroquine	NNP
cord-257258-hu9oxea1	38	2	is	be	VBZ
cord-257258-hu9oxea1	38	3	not	not	RB
cord-257258-hu9oxea1	38	4	an	an	DT
cord-257258-hu9oxea1	38	5	innocuous	innocuous	JJ
cord-257258-hu9oxea1	38	6	agent	agent	NN
cord-257258-hu9oxea1	38	7	.	.	.
cord-257258-hu9oxea1	39	1	It	-PRON-	PRP
cord-257258-hu9oxea1	39	2	causes	cause	VBZ
cord-257258-hu9oxea1	39	3	retinal	retinal	JJ
cord-257258-hu9oxea1	39	4	degeneration	degeneration	NN
cord-257258-hu9oxea1	39	5	,	,	,
cord-257258-hu9oxea1	39	6	myopathy	myopathy	NN
cord-257258-hu9oxea1	39	7	,	,	,
cord-257258-hu9oxea1	39	8	QT	qt	NN
cord-257258-hu9oxea1	39	9	interval	interval	NN
cord-257258-hu9oxea1	39	10	elongation	elongation	NN
cord-257258-hu9oxea1	39	11	,	,	,
cord-257258-hu9oxea1	39	12	and	and	CC
cord-257258-hu9oxea1	39	13	rarely	rarely	RB
cord-257258-hu9oxea1	39	14	,	,	,
cord-257258-hu9oxea1	39	15	ventricular	ventricular	JJ
cord-257258-hu9oxea1	39	16	arrhythmias	arrhythmias	RB
cord-257258-hu9oxea1	39	17	.	.	.
cord-257258-hu9oxea1	40	1	It	-PRON-	PRP
cord-257258-hu9oxea1	40	2	is	be	VBZ
cord-257258-hu9oxea1	40	3	metabolized	metabolize	VBN
cord-257258-hu9oxea1	40	4	by	by	IN
cord-257258-hu9oxea1	40	5	hepatic	hepatic	JJ
cord-257258-hu9oxea1	40	6	P450	p450	JJ
cord-257258-hu9oxea1	40	7	enzymes	enzyme	NNS
cord-257258-hu9oxea1	40	8	and	and	CC
cord-257258-hu9oxea1	40	9	thus	thus	RB
cord-257258-hu9oxea1	40	10	is	be	VBZ
cord-257258-hu9oxea1	40	11	capable	capable	JJ
cord-257258-hu9oxea1	40	12	of	of	IN
cord-257258-hu9oxea1	40	13	significant	significant	JJ
cord-257258-hu9oxea1	40	14	interaction	interaction	NN
cord-257258-hu9oxea1	40	15	with	with	IN
cord-257258-hu9oxea1	40	16	antibiotics	antibiotic	NNS
cord-257258-hu9oxea1	40	17	,	,	,
cord-257258-hu9oxea1	40	18	sedatives	sedative	NNS
cord-257258-hu9oxea1	40	19	,	,	,
cord-257258-hu9oxea1	40	20	and	and	CC
cord-257258-hu9oxea1	40	21	other	other	JJ
cord-257258-hu9oxea1	40	22	medications	medication	NNS
cord-257258-hu9oxea1	40	23	commonly	commonly	RB
cord-257258-hu9oxea1	40	24	used	use	VBN
cord-257258-hu9oxea1	40	25	in	in	IN
cord-257258-hu9oxea1	40	26	the	the	DT
cord-257258-hu9oxea1	40	27	treatment	treatment	NN
cord-257258-hu9oxea1	40	28	of	of	IN
cord-257258-hu9oxea1	40	29	COVID-19	covid-19	JJ
cord-257258-hu9oxea1	40	30	patients	patient	NNS
cord-257258-hu9oxea1	40	31	.	.	.
cord-257258-hu9oxea1	41	1	In	in	IN
cord-257258-hu9oxea1	41	2	patients	patient	NNS
cord-257258-hu9oxea1	41	3	with	with	IN
cord-257258-hu9oxea1	41	4	hepatic	hepatic	JJ
cord-257258-hu9oxea1	41	5	failure	failure	NN
cord-257258-hu9oxea1	41	6	,	,	,
cord-257258-hu9oxea1	41	7	which	which	WDT
cord-257258-hu9oxea1	41	8	occurs	occur	VBZ
cord-257258-hu9oxea1	41	9	with	with	IN
cord-257258-hu9oxea1	41	10	multi	multi	JJ
cord-257258-hu9oxea1	41	11	-	-	JJ
cord-257258-hu9oxea1	41	12	organ	organ	JJ
cord-257258-hu9oxea1	41	13	failure	failure	NN
cord-257258-hu9oxea1	41	14	in	in	IN
cord-257258-hu9oxea1	41	15	acute	acute	JJ
cord-257258-hu9oxea1	41	16	respiratory	respiratory	JJ
cord-257258-hu9oxea1	41	17	distress	distress	NN
cord-257258-hu9oxea1	41	18	syndrome	syndrome	NN
cord-257258-hu9oxea1	41	19	associated	associate	VBN
cord-257258-hu9oxea1	41	20	with	with	IN
cord-257258-hu9oxea1	41	21	COVID-19	COVID-19	NNP
cord-257258-hu9oxea1	41	22	,	,	,
cord-257258-hu9oxea1	41	23	the	the	DT
cord-257258-hu9oxea1	41	24	clearance	clearance	NN
cord-257258-hu9oxea1	41	25	of	of	IN
cord-257258-hu9oxea1	41	26	hydroxychloroquine	hydroxychloroquine	NN
cord-257258-hu9oxea1	41	27	is	be	VBZ
cord-257258-hu9oxea1	41	28	delayed	delay	VBN
cord-257258-hu9oxea1	41	29	,	,	,
cord-257258-hu9oxea1	41	30	increasing	increase	VBG
cord-257258-hu9oxea1	41	31	the	the	DT
cord-257258-hu9oxea1	41	32	risk	risk	NN
cord-257258-hu9oxea1	41	33	of	of	IN
cord-257258-hu9oxea1	41	34	cardiac	cardiac	JJ
cord-257258-hu9oxea1	41	35	arrhythmias	arrhythmia	NNS
cord-257258-hu9oxea1	41	36	.	.	.
cord-257258-hu9oxea1	42	1	Its	-PRON-	PRP$
cord-257258-hu9oxea1	42	2	general	general	JJ
cord-257258-hu9oxea1	42	3	use	use	NN
cord-257258-hu9oxea1	42	4	in	in	IN
cord-257258-hu9oxea1	42	5	severely	severely	RB
cord-257258-hu9oxea1	42	6	ill	ill	JJ
cord-257258-hu9oxea1	42	7	COVID-19	covid-19	CD
cord-257258-hu9oxea1	42	8	patients	patient	NNS
cord-257258-hu9oxea1	42	9	,	,	,
cord-257258-hu9oxea1	42	10	outside	outside	RB
cord-257258-hu9oxea1	42	11	of	of	IN
cord-257258-hu9oxea1	42	12	a	a	DT
cord-257258-hu9oxea1	42	13	research	research	NN
cord-257258-hu9oxea1	42	14	setting	setting	NN
cord-257258-hu9oxea1	42	15	,	,	,
cord-257258-hu9oxea1	42	16	carries	carry	VBZ
cord-257258-hu9oxea1	42	17	the	the	DT
cord-257258-hu9oxea1	42	18	risk	risk	NN
cord-257258-hu9oxea1	42	19	of	of	IN
cord-257258-hu9oxea1	42	20	unexpected	unexpected	JJ
cord-257258-hu9oxea1	42	21	and	and	CC
cord-257258-hu9oxea1	42	22	potentially	potentially	RB
cord-257258-hu9oxea1	42	23	lethal	lethal	JJ
cord-257258-hu9oxea1	42	24	side	side	NN
cord-257258-hu9oxea1	42	25	effects	effect	NNS
cord-257258-hu9oxea1	42	26	,	,	,
cord-257258-hu9oxea1	42	27	while	while	IN
cord-257258-hu9oxea1	42	28	learning	learn	VBG
cord-257258-hu9oxea1	42	29	very	very	RB
cord-257258-hu9oxea1	42	30	little	little	RB
cord-257258-hu9oxea1	42	31	in	in	IN
cord-257258-hu9oxea1	42	32	the	the	DT
cord-257258-hu9oxea1	42	33	process	process	NN
cord-257258-hu9oxea1	42	34	.	.	.
cord-257258-hu9oxea1	43	1	Among	among	IN
cord-257258-hu9oxea1	43	2	the	the	DT
cord-257258-hu9oxea1	43	3	many	many	JJ
cord-257258-hu9oxea1	43	4	ongoing	ongoing	JJ
cord-257258-hu9oxea1	43	5	anti	anti	JJ
cord-257258-hu9oxea1	43	6	-	-	JJ
cord-257258-hu9oxea1	43	7	SARS	SARS	NNP
cord-257258-hu9oxea1	43	8	-	-	HYPH
cord-257258-hu9oxea1	43	9	CoV-2	CoV-2	NNP
cord-257258-hu9oxea1	43	10	trials	trial	NNS
cord-257258-hu9oxea1	43	11	,	,	,
cord-257258-hu9oxea1	43	12	two	two	CD
cord-257258-hu9oxea1	43	13	anti	anti	JJ
cord-257258-hu9oxea1	43	14	-	-	NNS
cord-257258-hu9oxea1	43	15	virals	viral	NNS
cord-257258-hu9oxea1	43	16	developed	develop	VBN
cord-257258-hu9oxea1	43	17	initially	initially	RB
cord-257258-hu9oxea1	43	18	against	against	IN
cord-257258-hu9oxea1	43	19	earlier	early	JJR
cord-257258-hu9oxea1	43	20	outbreaks	outbreak	NNS
cord-257258-hu9oxea1	43	21	have	have	VBP
cord-257258-hu9oxea1	43	22	resurfaced	resurface	VBN
cord-257258-hu9oxea1	43	23	[	[	-LRB-
cord-257258-hu9oxea1	43	24	6	6	CD
cord-257258-hu9oxea1	43	25	]	]	-RRB-
cord-257258-hu9oxea1	43	26	.	.	.
cord-257258-hu9oxea1	44	1	Remdesivir	Remdesivir	NNP
cord-257258-hu9oxea1	44	2	(	(	-LRB-
cord-257258-hu9oxea1	44	3	Gilead	Gilead	NNP
cord-257258-hu9oxea1	44	4	)	)	-RRB-
cord-257258-hu9oxea1	44	5	,	,	,
cord-257258-hu9oxea1	44	6	a	a	DT
cord-257258-hu9oxea1	44	7	reverse	reverse	JJ
cord-257258-hu9oxea1	44	8	transcriptase	transcriptase	NN
cord-257258-hu9oxea1	44	9	(	(	-LRB-
cord-257258-hu9oxea1	44	10	RT	RT	NNP
cord-257258-hu9oxea1	44	11	)	)	-RRB-
cord-257258-hu9oxea1	44	12	inhibitor	inhibitor	NN
cord-257258-hu9oxea1	44	13	designed	design	VBN
cord-257258-hu9oxea1	44	14	originally	originally	RB
cord-257258-hu9oxea1	44	15	against	against	IN
cord-257258-hu9oxea1	44	16	SARS	SARS	NNP
cord-257258-hu9oxea1	44	17	RT	RT	NNP
cord-257258-hu9oxea1	44	18	,	,	,
cord-257258-hu9oxea1	44	19	has	have	VBZ
cord-257258-hu9oxea1	44	20	in	in	IN
cord-257258-hu9oxea1	44	21	vitro	vitro	FW
cord-257258-hu9oxea1	44	22	activity	activity	NN
cord-257258-hu9oxea1	44	23	against	against	IN
cord-257258-hu9oxea1	44	24	SARS	SARS	NNP
cord-257258-hu9oxea1	44	25	-	-	HYPH
cord-257258-hu9oxea1	44	26	CoV-2	CoV-2	NNP
cord-257258-hu9oxea1	44	27	and	and	CC
cord-257258-hu9oxea1	44	28	is	be	VBZ
cord-257258-hu9oxea1	44	29	currently	currently	RB
cord-257258-hu9oxea1	44	30	undergoing	undergo	VBG
cord-257258-hu9oxea1	44	31	trials	trial	NNS
cord-257258-hu9oxea1	44	32	in	in	IN
cord-257258-hu9oxea1	44	33	multiple	multiple	JJ
cord-257258-hu9oxea1	44	34	U.S.	U.S.	NNP
cord-257258-hu9oxea1	44	35	centers	center	NNS
cord-257258-hu9oxea1	44	36	and	and	CC
cord-257258-hu9oxea1	44	37	abroad	abroad	RB
cord-257258-hu9oxea1	44	38	.	.	.
cord-257258-hu9oxea1	45	1	In	in	IN
cord-257258-hu9oxea1	45	2	a	a	DT
cord-257258-hu9oxea1	45	3	preliminary	preliminary	JJ
cord-257258-hu9oxea1	45	4	report	report	NN
cord-257258-hu9oxea1	45	5	of	of	IN
cord-257258-hu9oxea1	45	6	53	53	CD
cord-257258-hu9oxea1	45	7	patients	patient	NNS
cord-257258-hu9oxea1	45	8	in	in	IN
cord-257258-hu9oxea1	45	9	a	a	DT
cord-257258-hu9oxea1	45	10	multi	multi	JJ
cord-257258-hu9oxea1	45	11	-	-	JJ
cord-257258-hu9oxea1	45	12	institutional	institutional	JJ
cord-257258-hu9oxea1	45	13	compassionate	compassionate	JJ
cord-257258-hu9oxea1	45	14	use	use	NN
cord-257258-hu9oxea1	45	15	cohort	cohort	NN
cord-257258-hu9oxea1	45	16	,	,	,
cord-257258-hu9oxea1	45	17	including	include	VBG
cord-257258-hu9oxea1	45	18	a	a	DT
cord-257258-hu9oxea1	45	19	spectrum	spectrum	NN
cord-257258-hu9oxea1	45	20	of	of	IN
cord-257258-hu9oxea1	45	21	illness	illness	NN
cord-257258-hu9oxea1	45	22	severity	severity	NN
cord-257258-hu9oxea1	45	23	,	,	,
cord-257258-hu9oxea1	45	24	68	68	CD
cord-257258-hu9oxea1	45	25	%	%	NN
cord-257258-hu9oxea1	45	26	had	have	VBD
cord-257258-hu9oxea1	45	27	improvement	improvement	NN
cord-257258-hu9oxea1	45	28	in	in	IN
cord-257258-hu9oxea1	45	29	oxygenation	oxygenation	NN
cord-257258-hu9oxea1	45	30	;	;	:
cord-257258-hu9oxea1	45	31	however	however	RB
cord-257258-hu9oxea1	45	32	,	,	,
cord-257258-hu9oxea1	45	33	the	the	DT
cord-257258-hu9oxea1	45	34	study	study	NN
cord-257258-hu9oxea1	45	35	lacked	lack	VBD
cord-257258-hu9oxea1	45	36	a	a	DT
cord-257258-hu9oxea1	45	37	control	control	NN
cord-257258-hu9oxea1	45	38	group	group	NN
cord-257258-hu9oxea1	45	39	,	,	,
cord-257258-hu9oxea1	45	40	so	so	CC
cord-257258-hu9oxea1	45	41	the	the	DT
cord-257258-hu9oxea1	45	42	benefit	benefit	NN
cord-257258-hu9oxea1	45	43	is	be	VBZ
cord-257258-hu9oxea1	45	44	difficult	difficult	JJ
cord-257258-hu9oxea1	45	45	to	to	TO
cord-257258-hu9oxea1	45	46	assess	assess	VB
cord-257258-hu9oxea1	45	47	[	[	-LRB-
cord-257258-hu9oxea1	45	48	7	7	CD
cord-257258-hu9oxea1	45	49	]	]	-RRB-
cord-257258-hu9oxea1	45	50	.	.	.
cord-257258-hu9oxea1	46	1	Favipiravir	Favipiravir	NNP
cord-257258-hu9oxea1	46	2	(	(	-LRB-
cord-257258-hu9oxea1	46	3	Fujifilm	Fujifilm	NNP
cord-257258-hu9oxea1	46	4	)	)	-RRB-
cord-257258-hu9oxea1	46	5	,	,	,
cord-257258-hu9oxea1	46	6	another	another	DT
cord-257258-hu9oxea1	46	7	viral	viral	JJ
cord-257258-hu9oxea1	46	8	replication	replication	NN
cord-257258-hu9oxea1	46	9	inhibitor	inhibitor	NN
cord-257258-hu9oxea1	46	10	designed	design	VBN
cord-257258-hu9oxea1	46	11	for	for	IN
cord-257258-hu9oxea1	46	12	treatment	treatment	NN
cord-257258-hu9oxea1	46	13	of	of	IN
cord-257258-hu9oxea1	46	14	influenza	influenza	NN
cord-257258-hu9oxea1	46	15	,	,	,
cord-257258-hu9oxea1	46	16	is	be	VBZ
cord-257258-hu9oxea1	46	17	also	also	RB
cord-257258-hu9oxea1	46	18	undergoing	undergo	VBG
cord-257258-hu9oxea1	46	19	randomized	randomized	JJ
cord-257258-hu9oxea1	46	20	trials	trial	NNS
cord-257258-hu9oxea1	46	21	in	in	IN
cord-257258-hu9oxea1	46	22	the	the	DT
cord-257258-hu9oxea1	46	23	U.S.	U.S.	NNP
cord-257258-hu9oxea1	46	24	and	and	CC
cord-257258-hu9oxea1	46	25	abroad	abroad	RB
cord-257258-hu9oxea1	46	26	.	.	.
cord-257258-hu9oxea1	47	1	Selinexor	Selinexor	NNP
cord-257258-hu9oxea1	47	2	,	,	,
cord-257258-hu9oxea1	47	3	a	a	DT
cord-257258-hu9oxea1	47	4	candidate	candidate	NN
cord-257258-hu9oxea1	47	5	anti	anti	JJ
cord-257258-hu9oxea1	47	6	-	-	JJ
cord-257258-hu9oxea1	47	7	cancer	cancer	JJ
cord-257258-hu9oxea1	47	8	drug	drug	NN
cord-257258-hu9oxea1	47	9	that	that	WDT
cord-257258-hu9oxea1	47	10	inhibits	inhibit	VBZ
cord-257258-hu9oxea1	47	11	nuclear	nuclear	JJ
cord-257258-hu9oxea1	47	12	export	export	NN
cord-257258-hu9oxea1	47	13	of	of	IN
cord-257258-hu9oxea1	47	14	viral	viral	JJ
cord-257258-hu9oxea1	47	15	proteins	protein	NNS
cord-257258-hu9oxea1	47	16	,	,	,
cord-257258-hu9oxea1	47	17	is	be	VBZ
cord-257258-hu9oxea1	47	18	also	also	RB
cord-257258-hu9oxea1	47	19	the	the	DT
cord-257258-hu9oxea1	47	20	subject	subject	NN
cord-257258-hu9oxea1	47	21	of	of	IN
cord-257258-hu9oxea1	47	22	expanded	expand	VBN
cord-257258-hu9oxea1	47	23	studies	study	NNS
cord-257258-hu9oxea1	47	24	against	against	IN
cord-257258-hu9oxea1	47	25	COVID-19	COVID-19	NNP
cord-257258-hu9oxea1	47	26	.	.	.
cord-257258-hu9oxea1	48	1	Efforts	effort	NNS
cord-257258-hu9oxea1	48	2	to	to	TO
cord-257258-hu9oxea1	48	3	discover	discover	VB
cord-257258-hu9oxea1	48	4	drugs	drug	NNS
cord-257258-hu9oxea1	48	5	for	for	IN
cord-257258-hu9oxea1	48	6	SARS	SARS	NNP
cord-257258-hu9oxea1	48	7	-	-	HYPH
cord-257258-hu9oxea1	48	8	CoV-2	CoV-2	NNP
cord-257258-hu9oxea1	48	9	infection	infection	NN
cord-257258-hu9oxea1	48	10	will	will	MD
cord-257258-hu9oxea1	48	11	likely	likely	RB
cord-257258-hu9oxea1	48	12	identify	identify	VB
cord-257258-hu9oxea1	48	13	more	more	RBR
cord-257258-hu9oxea1	48	14	effective	effective	JJ
cord-257258-hu9oxea1	48	15	and	and	CC
cord-257258-hu9oxea1	48	16	specifically	specifically	RB
cord-257258-hu9oxea1	48	17	-	-	HYPH
cord-257258-hu9oxea1	48	18	targeted	target	VBN
cord-257258-hu9oxea1	48	19	compounds	compound	NNS
cord-257258-hu9oxea1	48	20	[	[	-LRB-
cord-257258-hu9oxea1	48	21	6	6	CD
cord-257258-hu9oxea1	48	22	]	]	-RRB-
cord-257258-hu9oxea1	48	23	.	.	.
cord-257258-hu9oxea1	49	1	In	in	IN
cord-257258-hu9oxea1	49	2	recent	recent	JJ
cord-257258-hu9oxea1	49	3	years	year	NNS
cord-257258-hu9oxea1	49	4	the	the	DT
cord-257258-hu9oxea1	49	5	pharmaceutical	pharmaceutical	NN
cord-257258-hu9oxea1	49	6	industry	industry	NN
cord-257258-hu9oxea1	49	7	has	have	VBZ
cord-257258-hu9oxea1	49	8	had	have	VBN
cord-257258-hu9oxea1	49	9	remarkable	remarkable	JJ
cord-257258-hu9oxea1	49	10	success	success	NN
cord-257258-hu9oxea1	49	11	developing	develop	VBG
cord-257258-hu9oxea1	49	12	antivirals	antiviral	NNS
cord-257258-hu9oxea1	49	13	against	against	IN
cord-257258-hu9oxea1	49	14	HIV	HIV	NNP
cord-257258-hu9oxea1	49	15	-	-	HYPH
cord-257258-hu9oxea1	49	16	AIDS	AIDS	NNP
cord-257258-hu9oxea1	49	17	,	,	,
cord-257258-hu9oxea1	49	18	hepatitis	hepatitis	NN
cord-257258-hu9oxea1	49	19	B	B	NNP
cord-257258-hu9oxea1	49	20	and	and	CC
cord-257258-hu9oxea1	49	21	C	C	NNP
cord-257258-hu9oxea1	49	22	,	,	,
cord-257258-hu9oxea1	49	23	and	and	CC
cord-257258-hu9oxea1	49	24	herpes	herpes	NN
cord-257258-hu9oxea1	49	25	viruses	virus	NNS
cord-257258-hu9oxea1	49	26	.	.	.
cord-257258-hu9oxea1	50	1	There	there	EX
cord-257258-hu9oxea1	50	2	are	be	VBP
cord-257258-hu9oxea1	50	3	obvious	obvious	JJ
cord-257258-hu9oxea1	50	4	SARS	SARS	NNP
cord-257258-hu9oxea1	50	5	-	-	HYPH
cord-257258-hu9oxea1	50	6	CoV-2	CoV-2	NNP
cord-257258-hu9oxea1	50	7	targets	target	NNS
cord-257258-hu9oxea1	50	8	:	:	:
cord-257258-hu9oxea1	50	9	the	the	DT
cord-257258-hu9oxea1	50	10	viral	viral	JJ
cord-257258-hu9oxea1	50	11	reverse	reverse	NN
cord-257258-hu9oxea1	50	12	transcriptase	transcriptase	NN
cord-257258-hu9oxea1	50	13	necessary	necessary	JJ
cord-257258-hu9oxea1	50	14	for	for	IN
cord-257258-hu9oxea1	50	15	replication	replication	NN
cord-257258-hu9oxea1	50	16	,	,	,
cord-257258-hu9oxea1	50	17	a	a	DT
cord-257258-hu9oxea1	50	18	protease	protease	NN
cord-257258-hu9oxea1	50	19	TMPRSS2	TMPRSS2	NNP
cord-257258-hu9oxea1	50	20	required	require	VBN
cord-257258-hu9oxea1	50	21	to	to	TO
cord-257258-hu9oxea1	50	22	cleave	cleave	VB
cord-257258-hu9oxea1	50	23	the	the	DT
cord-257258-hu9oxea1	50	24	spike	spike	NN
cord-257258-hu9oxea1	50	25	protein	protein	NN
cord-257258-hu9oxea1	50	26	that	that	WDT
cord-257258-hu9oxea1	50	27	provides	provide	VBZ
cord-257258-hu9oxea1	50	28	viral	viral	JJ
cord-257258-hu9oxea1	50	29	entry	entry	NN
cord-257258-hu9oxea1	50	30	[	[	-LRB-
cord-257258-hu9oxea1	50	31	8	8	CD
cord-257258-hu9oxea1	50	32	]	]	-RRB-
cord-257258-hu9oxea1	50	33	,	,	,
cord-257258-hu9oxea1	50	34	the	the	DT
cord-257258-hu9oxea1	50	35	ACE2	ACE2	NNP
cord-257258-hu9oxea1	50	36	receptor	receptor	NN
cord-257258-hu9oxea1	50	37	on	on	IN
cord-257258-hu9oxea1	50	38	lung	lung	NN
cord-257258-hu9oxea1	50	39	epithelium	epithelium	NN
cord-257258-hu9oxea1	50	40	that	that	WDT
cord-257258-hu9oxea1	50	41	interacts	interact	VBZ
cord-257258-hu9oxea1	50	42	with	with	IN
cord-257258-hu9oxea1	50	43	spike	spike	NN
cord-257258-hu9oxea1	50	44	,	,	,
cord-257258-hu9oxea1	50	45	and	and	CC
cord-257258-hu9oxea1	50	46	small	small	JJ
cord-257258-hu9oxea1	50	47	molecules	molecule	NNS
cord-257258-hu9oxea1	50	48	that	that	WDT
cord-257258-hu9oxea1	50	49	inhibit	inhibit	VBP
cord-257258-hu9oxea1	50	50	ACE2	ACE2	NNP
cord-257258-hu9oxea1	50	51	.	.	.
cord-257258-hu9oxea1	51	1	It	-PRON-	PRP
cord-257258-hu9oxea1	51	2	is	be	VBZ
cord-257258-hu9oxea1	51	3	possible	possible	JJ
cord-257258-hu9oxea1	51	4	,	,	,
cord-257258-hu9oxea1	51	5	although	although	IN
cord-257258-hu9oxea1	51	6	unproven	unproven	JJ
cord-257258-hu9oxea1	51	7	,	,	,
cord-257258-hu9oxea1	51	8	that	that	IN
cord-257258-hu9oxea1	51	9	common	common	JJ
cord-257258-hu9oxea1	51	10	ACE2	ACE2	NNP
cord-257258-hu9oxea1	51	11	receptor	receptor	NN
cord-257258-hu9oxea1	51	12	inhibitors	inhibitor	NNS
cord-257258-hu9oxea1	51	13	now	now	RB
cord-257258-hu9oxea1	51	14	used	use	VBN
cord-257258-hu9oxea1	51	15	as	as	IN
cord-257258-hu9oxea1	51	16	anti	anti	JJ
cord-257258-hu9oxea1	51	17	-	-	JJ
cord-257258-hu9oxea1	51	18	hypertensives	hypertensives	NNP
cord-257258-hu9oxea1	51	19	would	would	MD
cord-257258-hu9oxea1	51	20	block	block	VB
cord-257258-hu9oxea1	51	21	viral	viral	JJ
cord-257258-hu9oxea1	51	22	entry	entry	NN
cord-257258-hu9oxea1	51	23	and	and	CC
cord-257258-hu9oxea1	51	24	mitigate	mitigate	VB
cord-257258-hu9oxea1	51	25	infection	infection	NN
cord-257258-hu9oxea1	51	26	.	.	.
cord-257258-hu9oxea1	52	1	Single	single	JJ
cord-257258-hu9oxea1	52	2	agent	agent	NN
cord-257258-hu9oxea1	52	3	antiviral	antiviral	JJ
cord-257258-hu9oxea1	52	4	therapy	therapy	NN
cord-257258-hu9oxea1	52	5	may	may	MD
cord-257258-hu9oxea1	52	6	not	not	RB
cord-257258-hu9oxea1	52	7	be	be	VB
cord-257258-hu9oxea1	52	8	sufficient	sufficient	JJ
cord-257258-hu9oxea1	52	9	.	.	.
cord-257258-hu9oxea1	53	1	Antivirals	antiviral	NNS
cord-257258-hu9oxea1	53	2	in	in	IN
cord-257258-hu9oxea1	53	3	combination	combination	NN
cord-257258-hu9oxea1	53	4	(	(	-LRB-
cord-257258-hu9oxea1	53	5	as	as	IN
cord-257258-hu9oxea1	53	6	they	-PRON-	PRP
cord-257258-hu9oxea1	53	7	are	be	VBP
cord-257258-hu9oxea1	53	8	now	now	RB
cord-257258-hu9oxea1	53	9	used	use	VBN
cord-257258-hu9oxea1	53	10	against	against	IN
cord-257258-hu9oxea1	53	11	HIV	HIV	NNP
cord-257258-hu9oxea1	53	12	and	and	CC
cord-257258-hu9oxea1	53	13	hepatitis	hepatitis	NN
cord-257258-hu9oxea1	53	14	infection	infection	NN
cord-257258-hu9oxea1	53	15	)	)	-RRB-
cord-257258-hu9oxea1	53	16	could	could	MD
cord-257258-hu9oxea1	53	17	be	be	VB
cord-257258-hu9oxea1	53	18	invaluable	invaluable	JJ
cord-257258-hu9oxea1	53	19	in	in	IN
cord-257258-hu9oxea1	53	20	prophylaxis	prophylaxis	NN
cord-257258-hu9oxea1	53	21	against	against	IN
cord-257258-hu9oxea1	53	22	infection	infection	NN
cord-257258-hu9oxea1	53	23	and	and	CC
cord-257258-hu9oxea1	53	24	in	in	IN
cord-257258-hu9oxea1	53	25	treating	treat	VBG
cord-257258-hu9oxea1	53	26	infection	infection	NN
cord-257258-hu9oxea1	53	27	before	before	IN
cord-257258-hu9oxea1	53	28	it	-PRON-	PRP
cord-257258-hu9oxea1	53	29	becomes	become	VBZ
cord-257258-hu9oxea1	53	30	life	life	NN
cord-257258-hu9oxea1	53	31	-	-	HYPH
cord-257258-hu9oxea1	53	32	threatening	threaten	VBG
cord-257258-hu9oxea1	53	33	.	.	.
cord-257258-hu9oxea1	54	1	A	a	DT
cord-257258-hu9oxea1	54	2	recent	recent	JJ
cord-257258-hu9oxea1	54	3	article	article	NN
cord-257258-hu9oxea1	54	4	in	in	IN
cord-257258-hu9oxea1	54	5	Science	Science	NNP
cord-257258-hu9oxea1	54	6	[	[	-LRB-
cord-257258-hu9oxea1	54	7	9	9	CD
cord-257258-hu9oxea1	54	8	]	]	-RRB-
cord-257258-hu9oxea1	54	9	describes	describe	VBZ
cord-257258-hu9oxea1	54	10	the	the	DT
cord-257258-hu9oxea1	54	11	relatively	relatively	RB
cord-257258-hu9oxea1	54	12	potent	potent	JJ
cord-257258-hu9oxea1	54	13	antiviral	antiviral	JJ
cord-257258-hu9oxea1	54	14	activity	activity	NN
cord-257258-hu9oxea1	54	15	of	of	IN
cord-257258-hu9oxea1	54	16	berta	berta	NNP
cord-257258-hu9oxea1	54	17	-	-	HYPH
cord-257258-hu9oxea1	54	18	D	D	NNP
cord-257258-hu9oxea1	54	19	-	-	HYPH
cord-257258-hu9oxea1	54	20	N4	N4	NNP
cord-257258-hu9oxea1	54	21	hydroxycytidine	hydroxycytidine	NN
cord-257258-hu9oxea1	54	22	against	against	IN
cord-257258-hu9oxea1	54	23	SARS	SARS	NNP
cord-257258-hu9oxea1	54	24	-	-	HYPH
cord-257258-hu9oxea1	54	25	CoV-2	CoV-2	NNP
cord-257258-hu9oxea1	54	26	in	in	IN
cord-257258-hu9oxea1	54	27	human	human	JJ
cord-257258-hu9oxea1	54	28	epithelial	epithelial	JJ
cord-257258-hu9oxea1	54	29	airway	airway	NN
cord-257258-hu9oxea1	54	30	cultures	culture	NNS
cord-257258-hu9oxea1	54	31	.	.	.
cord-257258-hu9oxea1	55	1	In	in	IN
cord-257258-hu9oxea1	55	2	vivo	vivo	NNP
cord-257258-hu9oxea1	55	3	studies	study	NNS
cord-257258-hu9oxea1	55	4	against	against	IN
cord-257258-hu9oxea1	55	5	the	the	DT
cord-257258-hu9oxea1	55	6	MERS	MERS	NNP
cord-257258-hu9oxea1	55	7	and	and	CC
cord-257258-hu9oxea1	55	8	SARS	SARS	NNP
cord-257258-hu9oxea1	55	9	viruses	virus	NNS
cord-257258-hu9oxea1	55	10	(	(	-LRB-
cord-257258-hu9oxea1	55	11	but	but	CC
cord-257258-hu9oxea1	55	12	not	not	RB
cord-257258-hu9oxea1	55	13	against	against	IN
cord-257258-hu9oxea1	55	14	SARS	SARS	NNP
cord-257258-hu9oxea1	55	15	-	-	HYPH
cord-257258-hu9oxea1	55	16	CoV-2	CoV-2	NNP
cord-257258-hu9oxea1	55	17	)	)	-RRB-
cord-257258-hu9oxea1	55	18	showed	show	VBD
cord-257258-hu9oxea1	55	19	partial	partial	JJ
cord-257258-hu9oxea1	55	20	protection	protection	NN
cord-257258-hu9oxea1	55	21	against	against	IN
cord-257258-hu9oxea1	55	22	lung	lung	NN
cord-257258-hu9oxea1	55	23	injury	injury	NN
cord-257258-hu9oxea1	55	24	,	,	,
cord-257258-hu9oxea1	55	25	but	but	CC
cord-257258-hu9oxea1	55	26	the	the	DT
cord-257258-hu9oxea1	55	27	effect	effect	NN
cord-257258-hu9oxea1	55	28	was	be	VBD
cord-257258-hu9oxea1	55	29	dependent	dependent	JJ
cord-257258-hu9oxea1	55	30	on	on	IN
cord-257258-hu9oxea1	55	31	early	early	JJ
cord-257258-hu9oxea1	55	32	drug	drug	NN
cord-257258-hu9oxea1	55	33	administration	administration	NN
cord-257258-hu9oxea1	55	34	after	after	IN
cord-257258-hu9oxea1	55	35	inoculation	inoculation	NN
cord-257258-hu9oxea1	55	36	of	of	IN
cord-257258-hu9oxea1	55	37	the	the	DT
cord-257258-hu9oxea1	55	38	virus	virus	NN
cord-257258-hu9oxea1	55	39	.	.	.
cord-257258-hu9oxea1	56	1	The	the	DT
cord-257258-hu9oxea1	56	2	study	study	NN
cord-257258-hu9oxea1	56	3	lacks	lack	VBZ
cord-257258-hu9oxea1	56	4	pharmacokinetic	pharmacokinetic	JJ
cord-257258-hu9oxea1	56	5	data	datum	NNS
cord-257258-hu9oxea1	56	6	to	to	TO
cord-257258-hu9oxea1	56	7	assure	assure	VB
cord-257258-hu9oxea1	56	8	that	that	IN
cord-257258-hu9oxea1	56	9	the	the	DT
cord-257258-hu9oxea1	56	10	drug	drug	NN
cord-257258-hu9oxea1	56	11	reaches	reach	VBZ
cord-257258-hu9oxea1	56	12	and	and	CC
cord-257258-hu9oxea1	56	13	maintains	maintain	VBZ
cord-257258-hu9oxea1	56	14	significant	significant	JJ
cord-257258-hu9oxea1	56	15	antiviral	antiviral	JJ
cord-257258-hu9oxea1	56	16	concentrations	concentration	NNS
cord-257258-hu9oxea1	56	17	in	in	IN
cord-257258-hu9oxea1	56	18	mice	mouse	NNS
cord-257258-hu9oxea1	56	19	.	.	.
cord-257258-hu9oxea1	57	1	Notably	notably	RB
cord-257258-hu9oxea1	57	2	,	,	,
cord-257258-hu9oxea1	57	3	the	the	DT
cord-257258-hu9oxea1	57	4	research	research	NN
cord-257258-hu9oxea1	57	5	lacks	lack	VBZ
cord-257258-hu9oxea1	57	6	a	a	DT
cord-257258-hu9oxea1	57	7	suitable	suitable	JJ
cord-257258-hu9oxea1	57	8	animal	animal	NN
cord-257258-hu9oxea1	57	9	model	model	NN
cord-257258-hu9oxea1	57	10	for	for	IN
cord-257258-hu9oxea1	57	11	SARS	SARS	NNP
cord-257258-hu9oxea1	57	12	-	-	HYPH
cord-257258-hu9oxea1	57	13	CoV-2	CoV-2	NNP
cord-257258-hu9oxea1	57	14	antiviral	antiviral	JJ
cord-257258-hu9oxea1	57	15	testing	testing	NN
cord-257258-hu9oxea1	57	16	,	,	,
cord-257258-hu9oxea1	57	17	but	but	CC
cord-257258-hu9oxea1	57	18	testing	test	VBG
cord-257258-hu9oxea1	57	19	against	against	IN
cord-257258-hu9oxea1	57	20	monkey	monkey	NN
cord-257258-hu9oxea1	57	21	models	model	NNS
cord-257258-hu9oxea1	57	22	may	may	MD
cord-257258-hu9oxea1	57	23	be	be	VB
cord-257258-hu9oxea1	57	24	possible	possible	JJ
cord-257258-hu9oxea1	57	25	in	in	IN
cord-257258-hu9oxea1	57	26	the	the	DT
cord-257258-hu9oxea1	57	27	near	near	JJ
cord-257258-hu9oxea1	57	28	future	future	NN
cord-257258-hu9oxea1	58	1	An	an	DT
cord-257258-hu9oxea1	58	2	additional	additional	JJ
cord-257258-hu9oxea1	58	3	intriguing	intriguing	JJ
cord-257258-hu9oxea1	58	4	therapeutic	therapeutic	JJ
cord-257258-hu9oxea1	58	5	possibility	possibility	NN
cord-257258-hu9oxea1	58	6	will	will	MD
cord-257258-hu9oxea1	58	7	be	be	VB
cord-257258-hu9oxea1	58	8	to	to	TO
cord-257258-hu9oxea1	58	9	suppress	suppress	VB
cord-257258-hu9oxea1	58	10	the	the	DT
cord-257258-hu9oxea1	58	11	cytokine	cytokine	NN
cord-257258-hu9oxea1	58	12	storm	storm	NN
cord-257258-hu9oxea1	58	13	that	that	WDT
cord-257258-hu9oxea1	58	14	results	result	VBZ
cord-257258-hu9oxea1	58	15	from	from	IN
cord-257258-hu9oxea1	58	16	the	the	DT
cord-257258-hu9oxea1	58	17	host	host	NN
cord-257258-hu9oxea1	58	18	inflammatory	inflammatory	JJ
cord-257258-hu9oxea1	58	19	response	response	NN
cord-257258-hu9oxea1	58	20	to	to	IN
cord-257258-hu9oxea1	58	21	the	the	DT
cord-257258-hu9oxea1	58	22	virus	virus	NN
cord-257258-hu9oxea1	58	23	.	.	.
cord-257258-hu9oxea1	59	1	The	the	DT
cord-257258-hu9oxea1	59	2	release	release	NN
cord-257258-hu9oxea1	59	3	of	of	IN
cord-257258-hu9oxea1	59	4	cytokines	cytokine	NNS
cord-257258-hu9oxea1	59	5	appears	appear	VBZ
cord-257258-hu9oxea1	59	6	to	to	TO
cord-257258-hu9oxea1	59	7	play	play	VB
cord-257258-hu9oxea1	59	8	a	a	DT
cord-257258-hu9oxea1	59	9	central	central	JJ
cord-257258-hu9oxea1	59	10	role	role	NN
cord-257258-hu9oxea1	59	11	in	in	IN
cord-257258-hu9oxea1	59	12	pulmonary	pulmonary	JJ
cord-257258-hu9oxea1	59	13	edema	edema	NN
cord-257258-hu9oxea1	59	14	,	,	,
cord-257258-hu9oxea1	59	15	inflammation	inflammation	NN
cord-257258-hu9oxea1	59	16	,	,	,
cord-257258-hu9oxea1	59	17	and	and	CC
cord-257258-hu9oxea1	59	18	respiratory	respiratory	JJ
cord-257258-hu9oxea1	59	19	failure	failure	NN
cord-257258-hu9oxea1	59	20	associated	associate	VBN
cord-257258-hu9oxea1	59	21	with	with	IN
cord-257258-hu9oxea1	59	22	COVID-19	COVID-19	NNP
cord-257258-hu9oxea1	59	23	[	[	-LRB-
cord-257258-hu9oxea1	59	24	10	10	CD
cord-257258-hu9oxea1	59	25	]	]	-RRB-
cord-257258-hu9oxea1	59	26	.	.	.
cord-257258-hu9oxea1	60	1	Although	although	IN
cord-257258-hu9oxea1	60	2	evidence	evidence	NN
cord-257258-hu9oxea1	60	3	is	be	VBZ
cord-257258-hu9oxea1	60	4	preliminary	preliminary	JJ
cord-257258-hu9oxea1	60	5	,	,	,
cord-257258-hu9oxea1	60	6	IL-6	IL-6	NNP
cord-257258-hu9oxea1	60	7	may	may	MD
cord-257258-hu9oxea1	60	8	be	be	VB
cord-257258-hu9oxea1	60	9	a	a	DT
cord-257258-hu9oxea1	60	10	key	key	JJ
cord-257258-hu9oxea1	60	11	component	component	NN
cord-257258-hu9oxea1	60	12	of	of	IN
cord-257258-hu9oxea1	60	13	the	the	DT
cord-257258-hu9oxea1	60	14	cytokine	cytokine	NN
cord-257258-hu9oxea1	60	15	storm	storm	NN
cord-257258-hu9oxea1	60	16	:	:	:
cord-257258-hu9oxea1	60	17	anecdotal	anecdotal	JJ
cord-257258-hu9oxea1	60	18	observations	observation	NNS
cord-257258-hu9oxea1	60	19	of	of	IN
cord-257258-hu9oxea1	60	20	beneficial	beneficial	JJ
cord-257258-hu9oxea1	60	21	responses	response	NNS
cord-257258-hu9oxea1	60	22	in	in	IN
cord-257258-hu9oxea1	60	23	patients	patient	NNS
cord-257258-hu9oxea1	60	24	treated	treat	VBN
cord-257258-hu9oxea1	60	25	with	with	IN
cord-257258-hu9oxea1	60	26	anti	anti	JJ
cord-257258-hu9oxea1	60	27	-	-	JJ
cord-257258-hu9oxea1	60	28	IL-6	il-6	JJ
cord-257258-hu9oxea1	60	29	receptor	receptor	NN
cord-257258-hu9oxea1	60	30	antibodies	antibody	NNS
cord-257258-hu9oxea1	60	31	support	support	VBP
cord-257258-hu9oxea1	60	32	this	this	DT
cord-257258-hu9oxea1	60	33	notion	notion	NN
cord-257258-hu9oxea1	60	34	.	.	.
cord-257258-hu9oxea1	61	1	Two	two	CD
cord-257258-hu9oxea1	61	2	IL-6	IL-6	NNP
cord-257258-hu9oxea1	61	3	antibodies	antibody	NNS
cord-257258-hu9oxea1	61	4	(	(	-LRB-
cord-257258-hu9oxea1	61	5	tocilizumab	tocilizumab	NNP
cord-257258-hu9oxea1	61	6	from	from	IN
cord-257258-hu9oxea1	61	7	Hoffman	Hoffman	NNP
cord-257258-hu9oxea1	61	8	-	-	HYPH
cord-257258-hu9oxea1	61	9	La	La	NNP
cord-257258-hu9oxea1	61	10	Roche	Roche	NNP
cord-257258-hu9oxea1	61	11	and	and	CC
cord-257258-hu9oxea1	61	12	sarilumab	sarilumab	NN
cord-257258-hu9oxea1	61	13	from	from	IN
cord-257258-hu9oxea1	61	14	Sanofi	Sanofi	NNP
cord-257258-hu9oxea1	61	15	)	)	-RRB-
cord-257258-hu9oxea1	61	16	are	be	VBP
cord-257258-hu9oxea1	61	17	currently	currently	RB
cord-257258-hu9oxea1	61	18	approved	approve	VBN
cord-257258-hu9oxea1	61	19	for	for	IN
cord-257258-hu9oxea1	61	20	rheumatoid	rheumatoid	NN
cord-257258-hu9oxea1	61	21	arthritis	arthritis	NN
cord-257258-hu9oxea1	61	22	and	and	CC
cord-257258-hu9oxea1	61	23	have	have	VBP
cord-257258-hu9oxea1	61	24	anecdotal	anecdotal	JJ
cord-257258-hu9oxea1	61	25	efficacy	efficacy	NN
cord-257258-hu9oxea1	61	26	in	in	IN
cord-257258-hu9oxea1	61	27	treating	treat	VBG
cord-257258-hu9oxea1	61	28	side	side	NN
cord-257258-hu9oxea1	61	29	effects	effect	NNS
cord-257258-hu9oxea1	61	30	of	of	IN
cord-257258-hu9oxea1	61	31	cancer	cancer	NN
cord-257258-hu9oxea1	61	32	immunotherapy	immunotherapy	NN
cord-257258-hu9oxea1	61	33	.	.	.
cord-257258-hu9oxea1	62	1	Multiple	multiple	JJ
cord-257258-hu9oxea1	62	2	trials	trial	NNS
cord-257258-hu9oxea1	62	3	of	of	IN
cord-257258-hu9oxea1	62	4	anti	anti	JJ
cord-257258-hu9oxea1	62	5	-	-	JJ
cord-257258-hu9oxea1	62	6	IL-6	il-6	JJ
cord-257258-hu9oxea1	62	7	receptor	receptor	NN
cord-257258-hu9oxea1	62	8	antibody	antibody	NN
cord-257258-hu9oxea1	62	9	in	in	IN
cord-257258-hu9oxea1	62	10	ventilator	ventilator	NN
cord-257258-hu9oxea1	62	11	-	-	HYPH
cord-257258-hu9oxea1	62	12	dependent	dependent	JJ
cord-257258-hu9oxea1	62	13	COVID-19	covid-19	JJ
cord-257258-hu9oxea1	62	14	infection	infection	NN
cord-257258-hu9oxea1	62	15	are	be	VBP
cord-257258-hu9oxea1	62	16	under	under	IN
cord-257258-hu9oxea1	62	17	way	way	NN
cord-257258-hu9oxea1	62	18	.	.	.
cord-257258-hu9oxea1	63	1	An	an	DT
cord-257258-hu9oxea1	63	2	inhibitor	inhibitor	NN
cord-257258-hu9oxea1	63	3	of	of	IN
cord-257258-hu9oxea1	63	4	the	the	DT
cord-257258-hu9oxea1	63	5	JAK2-STAT	jak2-stat	NN
cord-257258-hu9oxea1	63	6	pathway	pathway	NN
cord-257258-hu9oxea1	63	7	(	(	-LRB-
cord-257258-hu9oxea1	63	8	ruxolitinib	ruxolitinib	NNP
cord-257258-hu9oxea1	63	9	,	,	,
cord-257258-hu9oxea1	63	10	Novartis	Novartis	NNP
cord-257258-hu9oxea1	63	11	)	)	-RRB-
cord-257258-hu9oxea1	63	12	,	,	,
cord-257258-hu9oxea1	63	13	currently	currently	RB
cord-257258-hu9oxea1	63	14	used	use	VBN
cord-257258-hu9oxea1	63	15	against	against	IN
cord-257258-hu9oxea1	63	16	myelofibrosis	myelofibrosis	NNP
cord-257258-hu9oxea1	63	17	,	,	,
cord-257258-hu9oxea1	63	18	also	also	RB
cord-257258-hu9oxea1	63	19	blocks	block	VBZ
cord-257258-hu9oxea1	63	20	cytokine	cytokine	NN
cord-257258-hu9oxea1	63	21	production	production	NN
cord-257258-hu9oxea1	63	22	and	and	CC
cord-257258-hu9oxea1	63	23	will	will	MD
cord-257258-hu9oxea1	63	24	be	be	VB
cord-257258-hu9oxea1	63	25	tested	test	VBN
cord-257258-hu9oxea1	63	26	.	.	.
cord-257258-hu9oxea1	64	1	A	a	DT
cord-257258-hu9oxea1	64	2	more	more	RBR
cord-257258-hu9oxea1	64	3	detailed	detailed	JJ
cord-257258-hu9oxea1	64	4	understanding	understanding	NN
cord-257258-hu9oxea1	64	5	of	of	IN
cord-257258-hu9oxea1	64	6	the	the	DT
cord-257258-hu9oxea1	64	7	role	role	NN
cord-257258-hu9oxea1	64	8	of	of	IN
cord-257258-hu9oxea1	64	9	cytokines	cytokine	NNS
cord-257258-hu9oxea1	64	10	in	in	IN
cord-257258-hu9oxea1	64	11	lung	lung	NN
cord-257258-hu9oxea1	64	12	injury	injury	NN
cord-257258-hu9oxea1	64	13	would	would	MD
cord-257258-hu9oxea1	64	14	be	be	VB
cord-257258-hu9oxea1	64	15	invaluable	invaluable	JJ
cord-257258-hu9oxea1	64	16	,	,	,
cord-257258-hu9oxea1	64	17	and	and	CC
cord-257258-hu9oxea1	64	18	additional	additional	JJ
cord-257258-hu9oxea1	64	19	immune	immune	JJ
cord-257258-hu9oxea1	64	20	system	system	NN
cord-257258-hu9oxea1	64	21	targets	target	NNS
cord-257258-hu9oxea1	64	22	will	will	MD
cord-257258-hu9oxea1	64	23	likely	likely	RB
cord-257258-hu9oxea1	64	24	emerge	emerge	VB
cord-257258-hu9oxea1	64	25	from	from	IN
cord-257258-hu9oxea1	64	26	this	this	DT
cord-257258-hu9oxea1	64	27	research	research	NN
cord-257258-hu9oxea1	64	28	.	.	.
cord-257258-hu9oxea1	65	1	Finally	finally	RB
cord-257258-hu9oxea1	65	2	,	,	,
cord-257258-hu9oxea1	65	3	there	there	EX
cord-257258-hu9oxea1	65	4	is	be	VBZ
cord-257258-hu9oxea1	65	5	promise	promise	NN
cord-257258-hu9oxea1	65	6	in	in	IN
cord-257258-hu9oxea1	65	7	the	the	DT
cord-257258-hu9oxea1	65	8	use	use	NN
cord-257258-hu9oxea1	65	9	of	of	IN
cord-257258-hu9oxea1	65	10	hyperimmune	hyperimmune	NNP
cord-257258-hu9oxea1	65	11	serum	serum	NN
cord-257258-hu9oxea1	65	12	as	as	IN
cord-257258-hu9oxea1	65	13	passive	passive	JJ
cord-257258-hu9oxea1	65	14	treatment	treatment	NN
cord-257258-hu9oxea1	65	15	of	of	IN
cord-257258-hu9oxea1	65	16	desperately	desperately	RB
cord-257258-hu9oxea1	65	17	ill	ill	JJ
cord-257258-hu9oxea1	65	18	patients	patient	NNS
cord-257258-hu9oxea1	65	19	.	.	.
cord-257258-hu9oxea1	66	1	Very	very	RB
cord-257258-hu9oxea1	66	2	limited	limited	JJ
cord-257258-hu9oxea1	66	3	experience	experience	NN
cord-257258-hu9oxea1	66	4	,	,	,
cord-257258-hu9oxea1	66	5	anecdotal	anecdotal	JJ
cord-257258-hu9oxea1	66	6	at	at	IN
cord-257258-hu9oxea1	66	7	best	good	JJS
cord-257258-hu9oxea1	66	8	,	,	,
cord-257258-hu9oxea1	66	9	suggests	suggest	VBZ
cord-257258-hu9oxea1	66	10	that	that	IN
cord-257258-hu9oxea1	66	11	antibodies	antibody	NNS
cord-257258-hu9oxea1	66	12	can	can	MD
cord-257258-hu9oxea1	66	13	mitigate	mitigate	VB
cord-257258-hu9oxea1	66	14	infection	infection	NN
cord-257258-hu9oxea1	66	15	in	in	IN
cord-257258-hu9oxea1	66	16	these	these	DT
cord-257258-hu9oxea1	66	17	patients	patient	NNS
cord-257258-hu9oxea1	66	18	[	[	-LRB-
cord-257258-hu9oxea1	66	19	11	11	CD
cord-257258-hu9oxea1	66	20	]	]	-RRB-
cord-257258-hu9oxea1	66	21	.	.	.
cord-257258-hu9oxea1	67	1	Companies	company	NNS
cord-257258-hu9oxea1	67	2	are	be	VBP
cord-257258-hu9oxea1	67	3	investigating	investigate	VBG
cord-257258-hu9oxea1	67	4	the	the	DT
cord-257258-hu9oxea1	67	5	development	development	NN
cord-257258-hu9oxea1	67	6	of	of	IN
cord-257258-hu9oxea1	67	7	antiviral	antiviral	JJ
cord-257258-hu9oxea1	67	8	monoclonal	monoclonal	JJ
cord-257258-hu9oxea1	67	9	antibodies	antibody	NNS
cord-257258-hu9oxea1	67	10	for	for	IN
cord-257258-hu9oxea1	67	11	this	this	DT
cord-257258-hu9oxea1	67	12	purpose	purpose	NN
cord-257258-hu9oxea1	67	13	,	,	,
cord-257258-hu9oxea1	67	14	and	and	CC
cord-257258-hu9oxea1	67	15	convalescent	convalescent	JJ
cord-257258-hu9oxea1	67	16	sera	sera	NNP
cord-257258-hu9oxea1	67	17	are	be	VBP
cord-257258-hu9oxea1	67	18	also	also	RB
cord-257258-hu9oxea1	67	19	being	be	VBG
cord-257258-hu9oxea1	67	20	tested	test	VBN
cord-257258-hu9oxea1	67	21	.	.	.
cord-257258-hu9oxea1	68	1	In	in	IN
cord-257258-hu9oxea1	68	2	conclusion	conclusion	NN
cord-257258-hu9oxea1	68	3	,	,	,
cord-257258-hu9oxea1	68	4	from	from	IN
cord-257258-hu9oxea1	68	5	the	the	DT
cord-257258-hu9oxea1	68	6	perspective	perspective	NN
cord-257258-hu9oxea1	68	7	of	of	IN
cord-257258-hu9oxea1	68	8	long	long	JJ
cord-257258-hu9oxea1	68	9	-	-	HYPH
cord-257258-hu9oxea1	68	10	term	term	NN
cord-257258-hu9oxea1	68	11	control	control	NN
cord-257258-hu9oxea1	68	12	of	of	IN
cord-257258-hu9oxea1	68	13	coronavirus	coronavirus	NN
cord-257258-hu9oxea1	68	14	infection	infection	NN
cord-257258-hu9oxea1	68	15	,	,	,
cord-257258-hu9oxea1	68	16	both	both	DT
cord-257258-hu9oxea1	68	17	vaccines	vaccine	NNS
cord-257258-hu9oxea1	68	18	and	and	CC
cord-257258-hu9oxea1	68	19	antivirals	antiviral	NNS
cord-257258-hu9oxea1	68	20	will	will	MD
cord-257258-hu9oxea1	68	21	be	be	VB
cord-257258-hu9oxea1	68	22	necessary	necessary	JJ
cord-257258-hu9oxea1	68	23	to	to	TO
cord-257258-hu9oxea1	68	24	avoid	avoid	VB
cord-257258-hu9oxea1	68	25	the	the	DT
cord-257258-hu9oxea1	68	26	death	death	NN
cord-257258-hu9oxea1	68	27	and	and	CC
cord-257258-hu9oxea1	68	28	destruction	destruction	NN
cord-257258-hu9oxea1	68	29	imposed	impose	VBN
cord-257258-hu9oxea1	68	30	by	by	IN
cord-257258-hu9oxea1	68	31	the	the	DT
cord-257258-hu9oxea1	68	32	current	current	JJ
cord-257258-hu9oxea1	68	33	epidemic	epidemic	NN
cord-257258-hu9oxea1	68	34	.	.	.
cord-257258-hu9oxea1	69	1	Vastly	vastly	RB
cord-257258-hu9oxea1	69	2	improved	improve	VBN
cord-257258-hu9oxea1	69	3	preparedness	preparedness	NN
cord-257258-hu9oxea1	69	4	,	,	,
cord-257258-hu9oxea1	69	5	early	early	JJ
cord-257258-hu9oxea1	69	6	deployment	deployment	NN
cord-257258-hu9oxea1	69	7	of	of	IN
cord-257258-hu9oxea1	69	8	viral	viral	JJ
cord-257258-hu9oxea1	69	9	testing	testing	NN
cord-257258-hu9oxea1	69	10	,	,	,
cord-257258-hu9oxea1	69	11	and	and	CC
cord-257258-hu9oxea1	69	12	quarantine	quarantine	NN
cord-257258-hu9oxea1	69	13	of	of	IN
cord-257258-hu9oxea1	69	14	infected	infected	JJ
cord-257258-hu9oxea1	69	15	individuals	individual	NNS
cord-257258-hu9oxea1	69	16	will	will	MD
cord-257258-hu9oxea1	69	17	help	help	VB
cord-257258-hu9oxea1	69	18	limit	limit	VB
cord-257258-hu9oxea1	69	19	the	the	DT
cord-257258-hu9oxea1	69	20	spread	spread	NN
cord-257258-hu9oxea1	69	21	of	of	IN
cord-257258-hu9oxea1	69	22	the	the	DT
cord-257258-hu9oxea1	69	23	next	next	JJ
cord-257258-hu9oxea1	69	24	wave	wave	NN
cord-257258-hu9oxea1	69	25	of	of	IN
cord-257258-hu9oxea1	69	26	coronavirus	coronavirus	NN
cord-257258-hu9oxea1	69	27	infection	infection	NN
cord-257258-hu9oxea1	69	28	.	.	.
cord-257258-hu9oxea1	70	1	However	however	RB
cord-257258-hu9oxea1	70	2	,	,	,
cord-257258-hu9oxea1	70	3	vaccine	vaccine	NN
cord-257258-hu9oxea1	70	4	development	development	NN
cord-257258-hu9oxea1	70	5	and	and	CC
cord-257258-hu9oxea1	70	6	its	-PRON-	PRP$
cord-257258-hu9oxea1	70	7	worldwide	worldwide	JJ
cord-257258-hu9oxea1	70	8	implementation	implementation	NN
cord-257258-hu9oxea1	70	9	,	,	,
cord-257258-hu9oxea1	70	10	coupled	couple	VBN
cord-257258-hu9oxea1	70	11	with	with	IN
cord-257258-hu9oxea1	70	12	effective	effective	JJ
cord-257258-hu9oxea1	70	13	antiviral	antiviral	JJ
cord-257258-hu9oxea1	70	14	treatment	treatment	NN
cord-257258-hu9oxea1	70	15	,	,	,
cord-257258-hu9oxea1	70	16	will	will	MD
cord-257258-hu9oxea1	70	17	be	be	VB
cord-257258-hu9oxea1	70	18	required	require	VBN
cord-257258-hu9oxea1	70	19	to	to	TO
cord-257258-hu9oxea1	70	20	control	control	VB
cord-257258-hu9oxea1	70	21	COVID-19	covid-19	VB
cord-257258-hu9oxea1	70	22	and	and	CC
cord-257258-hu9oxea1	70	23	prevent	prevent	VB
cord-257258-hu9oxea1	70	24	another	another	DT
cord-257258-hu9oxea1	70	25	pandemic	pandemic	NN
cord-257258-hu9oxea1	70	26	.	.	.
cord-257258-hu9oxea1	71	1	In	in	IN
cord-257258-hu9oxea1	71	2	order	order	NN
cord-257258-hu9oxea1	71	3	to	to	TO
cord-257258-hu9oxea1	71	4	be	be	VB
cord-257258-hu9oxea1	71	5	ready	ready	JJ
cord-257258-hu9oxea1	71	6	for	for	IN
cord-257258-hu9oxea1	71	7	the	the	DT
cord-257258-hu9oxea1	71	8	next	next	JJ
cord-257258-hu9oxea1	71	9	iteration	iteration	NN
cord-257258-hu9oxea1	71	10	of	of	IN
cord-257258-hu9oxea1	71	11	COVID-19	COVID-19	NNP
cord-257258-hu9oxea1	71	12	,	,	,
cord-257258-hu9oxea1	71	13	the	the	DT
cord-257258-hu9oxea1	71	14	worldwide	worldwide	JJ
cord-257258-hu9oxea1	71	15	medical	medical	JJ
cord-257258-hu9oxea1	71	16	community	community	NN
cord-257258-hu9oxea1	71	17	will	will	MD
cord-257258-hu9oxea1	71	18	need	need	VB
cord-257258-hu9oxea1	71	19	to	to	TO
cord-257258-hu9oxea1	71	20	cooperate	cooperate	VB
cord-257258-hu9oxea1	71	21	in	in	IN
cord-257258-hu9oxea1	71	22	conducting	conduct	VBG
cord-257258-hu9oxea1	71	23	extensive	extensive	JJ
cord-257258-hu9oxea1	71	24	clinical	clinical	JJ
cord-257258-hu9oxea1	71	25	trials	trial	NNS
cord-257258-hu9oxea1	71	26	of	of	IN
cord-257258-hu9oxea1	71	27	vaccines	vaccine	NNS
cord-257258-hu9oxea1	71	28	,	,	,
cord-257258-hu9oxea1	71	29	antivirals	antiviral	NNS
cord-257258-hu9oxea1	71	30	,	,	,
cord-257258-hu9oxea1	71	31	and	and	CC
cord-257258-hu9oxea1	71	32	immune	immune	JJ
cord-257258-hu9oxea1	71	33	therapies	therapy	NNS
cord-257258-hu9oxea1	71	34	on	on	IN
cord-257258-hu9oxea1	71	35	an	an	DT
cord-257258-hu9oxea1	71	36	accelerated	accelerated	JJ
cord-257258-hu9oxea1	71	37	time	time	NN
cord-257258-hu9oxea1	71	38	scale	scale	NN
cord-257258-hu9oxea1	71	39	.	.	.
cord-257258-hu9oxea1	72	1	Sadly	sadly	RB
cord-257258-hu9oxea1	72	2	,	,	,
cord-257258-hu9oxea1	72	3	but	but	CC
cord-257258-hu9oxea1	72	4	necessarily	necessarily	RB
cord-257258-hu9oxea1	72	5	,	,	,
cord-257258-hu9oxea1	72	6	this	this	DT
cord-257258-hu9oxea1	72	7	worldwide	worldwide	JJ
cord-257258-hu9oxea1	72	8	effort	effort	NN
cord-257258-hu9oxea1	72	9	will	will	MD
cord-257258-hu9oxea1	72	10	divert	divert	VB
cord-257258-hu9oxea1	72	11	resources	resource	NNS
cord-257258-hu9oxea1	72	12	from	from	IN
cord-257258-hu9oxea1	72	13	other	other	JJ
cord-257258-hu9oxea1	72	14	areas	area	NNS
cord-257258-hu9oxea1	72	15	of	of	IN
cord-257258-hu9oxea1	72	16	medical	medical	JJ
cord-257258-hu9oxea1	72	17	research	research	NN
cord-257258-hu9oxea1	72	18	,	,	,
cord-257258-hu9oxea1	72	19	including	include	VBG
cord-257258-hu9oxea1	72	20	cancer	cancer	NN
cord-257258-hu9oxea1	72	21	research	research	NN
cord-257258-hu9oxea1	72	22	,	,	,
cord-257258-hu9oxea1	72	23	for	for	IN
cord-257258-hu9oxea1	72	24	the	the	DT
cord-257258-hu9oxea1	72	25	foreseeable	foreseeable	JJ
cord-257258-hu9oxea1	72	26	future	future	NN
cord-257258-hu9oxea1	72	27	,	,	,
cord-257258-hu9oxea1	72	28	but	but	CC
cord-257258-hu9oxea1	72	29	we	-PRON-	PRP
cord-257258-hu9oxea1	72	30	have	have	VBP
cord-257258-hu9oxea1	72	31	no	no	DT
cord-257258-hu9oxea1	72	32	choice	choice	NN
cord-257258-hu9oxea1	72	33	.	.	.
cord-257258-hu9oxea1	73	1	COVID-19	covid-19	JJ
cord-257258-hu9oxea1	73	2	vaccine	vaccine	NN
cord-257258-hu9oxea1	73	3	frontrunners	frontrunner	NNS
cord-257258-hu9oxea1	73	4	.	.	.
cord-257258-hu9oxea1	74	1	The	the	DT
cord-257258-hu9oxea1	74	2	Scientist	Scientist	NNP
cord-257258-hu9oxea1	74	3	Developing	develop	VBG
cord-257258-hu9oxea1	74	4	COVID-19	COVID-19	,
cord-257258-hu9oxea1	74	5	vaccines	vaccine	NNS
cord-257258-hu9oxea1	74	6	at	at	IN
cord-257258-hu9oxea1	74	7	pandemic	pandemic	NN
cord-257258-hu9oxea1	74	8	speed	speed	NN
cord-257258-hu9oxea1	74	9	World	World	NNP
cord-257258-hu9oxea1	74	10	Health	Health	NNP
cord-257258-hu9oxea1	74	11	Organization	Organization	NNP
cord-257258-hu9oxea1	74	12	.	.	.
cord-257258-hu9oxea1	75	1	Draft	draft	NN
cord-257258-hu9oxea1	75	2	landscape	landscape	NN
cord-257258-hu9oxea1	75	3	of	of	IN
cord-257258-hu9oxea1	75	4	COVID-19	covid-19	JJ
cord-257258-hu9oxea1	75	5	candidate	candidate	NN
cord-257258-hu9oxea1	75	6	vaccines	vaccine	NNS
cord-257258-hu9oxea1	75	7	Hydroxychloroquine	Hydroxychloroquine	NNP
cord-257258-hu9oxea1	75	8	and	and	CC
cord-257258-hu9oxea1	75	9	azithromycin	azithromycin	NNP
cord-257258-hu9oxea1	75	10	as	as	IN
cord-257258-hu9oxea1	75	11	a	a	DT
cord-257258-hu9oxea1	75	12	treatment	treatment	NN
cord-257258-hu9oxea1	75	13	of	of	IN
cord-257258-hu9oxea1	75	14	COVID-19	covid-19	NN
cord-257258-hu9oxea1	75	15	:	:	:
cord-257258-hu9oxea1	75	16	Results	result	NNS
cord-257258-hu9oxea1	75	17	of	of	IN
cord-257258-hu9oxea1	75	18	an	an	DT
cord-257258-hu9oxea1	75	19	open	open	JJ
cord-257258-hu9oxea1	75	20	-	-	HYPH
cord-257258-hu9oxea1	75	21	label	label	NN
cord-257258-hu9oxea1	75	22	non	non	JJ
cord-257258-hu9oxea1	75	23	-	-	JJ
cord-257258-hu9oxea1	75	24	randomized	randomized	JJ
cord-257258-hu9oxea1	75	25	clinical	clinical	JJ
cord-257258-hu9oxea1	75	26	trial	trial	NN
cord-257258-hu9oxea1	75	27	International	International	NNP
cord-257258-hu9oxea1	75	28	Society	Society	NNP
cord-257258-hu9oxea1	75	29	of	of	IN
cord-257258-hu9oxea1	75	30	Antimicrobial	Antimicrobial	NNP
cord-257258-hu9oxea1	75	31	Chemotherapy	Chemotherapy	NNP
cord-257258-hu9oxea1	75	32	Statement	Statement	NNP
cord-257258-hu9oxea1	75	33	on	on	IN
cord-257258-hu9oxea1	75	34	IJAA	IJAA	NNP
cord-257258-hu9oxea1	75	35	paper	paper	NN
cord-257258-hu9oxea1	75	36	World	World	NNP
cord-257258-hu9oxea1	75	37	Health	Health	NNP
cord-257258-hu9oxea1	75	38	Organization	Organization	NNP
cord-257258-hu9oxea1	75	39	.	.	.
cord-257258-hu9oxea1	76	1	R	R	NNP
cord-257258-hu9oxea1	76	2	&	&	CC
cord-257258-hu9oxea1	76	3	D	D	NNP
cord-257258-hu9oxea1	76	4	blueprint	blueprint	NN
cord-257258-hu9oxea1	76	5	:	:	:
cord-257258-hu9oxea1	77	1	Informal	informal	JJ
cord-257258-hu9oxea1	77	2	consultation	consultation	NN
cord-257258-hu9oxea1	77	3	on	on	IN
cord-257258-hu9oxea1	77	4	prioritization	prioritization	NN
cord-257258-hu9oxea1	77	5	of	of	IN
cord-257258-hu9oxea1	77	6	candidate	candidate	NN
cord-257258-hu9oxea1	77	7	therapeutic	therapeutic	JJ
cord-257258-hu9oxea1	77	8	agents	agent	NNS
cord-257258-hu9oxea1	77	9	for	for	IN
cord-257258-hu9oxea1	77	10	use	use	NN
cord-257258-hu9oxea1	77	11	in	in	IN
cord-257258-hu9oxea1	77	12	novel	novel	JJ
cord-257258-hu9oxea1	77	13	coronavirus	coronavirus	NN
cord-257258-hu9oxea1	77	14	2019	2019	CD
cord-257258-hu9oxea1	77	15	infection	infection	NN
cord-257258-hu9oxea1	77	16	Compassionate	compassionate	JJ
cord-257258-hu9oxea1	77	17	use	use	NN
cord-257258-hu9oxea1	77	18	of	of	IN
cord-257258-hu9oxea1	77	19	remdesivir	remdesivir	NNS
cord-257258-hu9oxea1	77	20	for	for	IN
cord-257258-hu9oxea1	77	21	patients	patient	NNS
cord-257258-hu9oxea1	77	22	with	with	IN
cord-257258-hu9oxea1	77	23	severe	severe	JJ
cord-257258-hu9oxea1	77	24	COVID-19	COVID-19	NNP
cord-257258-hu9oxea1	77	25	Hydroxychloroquine	Hydroxychloroquine	NNP
cord-257258-hu9oxea1	77	26	,	,	,
cord-257258-hu9oxea1	77	27	a	a	DT
cord-257258-hu9oxea1	77	28	less	less	RBR
cord-257258-hu9oxea1	77	29	toxic	toxic	JJ
cord-257258-hu9oxea1	77	30	derivative	derivative	NN
cord-257258-hu9oxea1	77	31	of	of	IN
cord-257258-hu9oxea1	77	32	chloroquine	chloroquine	NN
cord-257258-hu9oxea1	77	33	,	,	,
cord-257258-hu9oxea1	77	34	is	be	VBZ
cord-257258-hu9oxea1	77	35	effective	effective	JJ
cord-257258-hu9oxea1	77	36	in	in	IN
cord-257258-hu9oxea1	77	37	inhibiting	inhibit	VBG
cord-257258-hu9oxea1	77	38	SARS	SARS	NNP
cord-257258-hu9oxea1	77	39	-	-	HYPH
cord-257258-hu9oxea1	77	40	CoV-2	CoV-2	NNP
cord-257258-hu9oxea1	77	41	infection	infection	NN
cord-257258-hu9oxea1	77	42	in	in	IN
cord-257258-hu9oxea1	77	43	vitro	vitro	FW
cord-257258-hu9oxea1	78	1	An	an	DT
cord-257258-hu9oxea1	78	2	orally	orally	RB
cord-257258-hu9oxea1	78	3	bioavailable	bioavailable	JJ
cord-257258-hu9oxea1	78	4	broad	broad	JJ
cord-257258-hu9oxea1	78	5	spectrum	spectrum	NN
cord-257258-hu9oxea1	78	6	antiviral	antiviral	NN
cord-257258-hu9oxea1	78	7	inhibits	inhibit	VBZ
cord-257258-hu9oxea1	78	8	SARS	SARS	NNP
cord-257258-hu9oxea1	78	9	-	-	HYPH
cord-257258-hu9oxea1	78	10	CoV-2	CoV-2	NNP
cord-257258-hu9oxea1	78	11	in	in	IN
cord-257258-hu9oxea1	78	12	human	human	JJ
cord-257258-hu9oxea1	78	13	airway	airway	NN
cord-257258-hu9oxea1	78	14	epithelial	epithelial	JJ
cord-257258-hu9oxea1	78	15	cell	cell	NN
cord-257258-hu9oxea1	78	16	cultures	culture	NNS
cord-257258-hu9oxea1	78	17	and	and	CC
cord-257258-hu9oxea1	78	18	multiple	multiple	JJ
cord-257258-hu9oxea1	78	19	coronaviruses	coronaviruse	NNS
cord-257258-hu9oxea1	78	20	in	in	IN
cord-257258-hu9oxea1	78	21	mice	mouse	NNS
cord-257258-hu9oxea1	79	1	Are	be	VBP
cord-257258-hu9oxea1	79	2	IL-6	IL-6	NNP
cord-257258-hu9oxea1	79	3	inhibitors	inhibitor	NNS
cord-257258-hu9oxea1	79	4	one	one	CD
cord-257258-hu9oxea1	79	5	key	key	NN
cord-257258-hu9oxea1	79	6	to	to	IN
cord-257258-hu9oxea1	79	7	COVID-19	covid-19	VB
cord-257258-hu9oxea1	79	8	?	?	.
cord-257258-hu9oxea1	80	1	EUSA	EUSA	NNP
cord-257258-hu9oxea1	80	2	Pharma	Pharma	NNP
cord-257258-hu9oxea1	80	3	joins	join	VBZ
cord-257258-hu9oxea1	80	4	Sanofi	Sanofi	NNP
cord-257258-hu9oxea1	80	5	,	,	,
cord-257258-hu9oxea1	80	6	Regeneron	Regeneron	NNP
cord-257258-hu9oxea1	80	7	in	in	IN
cord-257258-hu9oxea1	80	8	rolling	roll	VBG
cord-257258-hu9oxea1	80	9	out	out	RP
cord-257258-hu9oxea1	80	10	trials	trial	NNS
cord-257258-hu9oxea1	80	11	Treatment	Treatment	NNP
cord-257258-hu9oxea1	80	12	of	of	IN
cord-257258-hu9oxea1	80	13	5	5	CD
cord-257258-hu9oxea1	80	14	critically	critically	RB
cord-257258-hu9oxea1	80	15	ill	ill	JJ
cord-257258-hu9oxea1	80	16	patients	patient	NNS
cord-257258-hu9oxea1	80	17	with	with	IN
cord-257258-hu9oxea1	80	18	COVID-19	COVID-19	NNP
cord-257258-hu9oxea1	80	19	with	with	IN
cord-257258-hu9oxea1	80	20	convalescent	convalescent	JJ
cord-257258-hu9oxea1	80	21	plasma	plasma	NN